



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/00	A2	(11) International Publication Number: WO 99/10375 (43) International Publication Date: 4 March 1999 (04.03.99)
(21) International Application Number: PCT/EP98/05285 (22) International Filing Date: 17 August 1998 (17.08.98) (30) Priority Data: 9717953.5 22 August 1997 (22.08.97) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM BIOLOGICALS S.A. [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): BRUCK, Claudine [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). CABEZON SILVA, Teresa [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). DELISSE, Anne-Marie, Eva, Fernande [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). GERARD, Catherine, Marie, Ghislaine [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). LOMBARDO-BENCHEIKH, Angela [FR/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE).		(74) Agent: DALTON, Marcus, Jonathan, William; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: VACCINE (57) Abstract The present invention provides Human Papilloma Virus (HPV) fusion proteins, linked to an immunological fusion partner that provides T helper epitopes to the HPV antigen. Vaccine formulations are provided that are useful in the treatment or Prophylaxis of HPV induced lesions.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroun	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

VACCINE

The present invention relates to fusions proteins, comprising a protein or part of a protein that provides T helper epitopes and an antigen from a human-papilloma virus that find utility in the treatment or prophylaxis of human papilloma induced tumours. In particular the invention relates to fusion proteins comprising an E6 or E7 protein from HPV strain 16 or 18 linked to protein D from Heamophilus influenza B.

Papillomaviruses are small naked DNA tumour viruses (7.9 kilobases, double strand), which are highly species-specific. Over 70 individual human papillomavirus (HPV) genotypes have been described. Papillomaviruses are classified on the basis of species of origin (human, bovine etc.) and of the degree of genetic relatedness with other papillomaviruses from the same species. HPVs are generally specific for the skin or mucosal surfaces and have been broadly classified into "low" and "high" risk on the basis of rare and common, respectively, detection in abnormal or tumour tissue.

Low risk HPVs usually cause benign *lesions* (warts or papillomas) that persist for several months or years. High risk HPVs are associated with cancer. The strongest positive association between an HPV virus and human cancer is that which exist between HPV 16 and 18 and cervical carcinoma. More than ten other HPV types have also been found in cervical carcinomas including HPV 31 and HPV 33 although at less frequency.

Genital HPV infection in young sexually active women is common and most individuals either clear the infection, or if lesions develop, these regress. Only a subset of infected individuals has lesions which progress to high grade intraepithelial neoplasia and only a fraction of these progress further to invasive carcinoma.

The molecular events leading to HPV infection have not been clearly established. The lack of an adequate *in vitro* system to propagate human papillomaviruses has hampered the progress to a best information about the viral cycle.

Today, the different types of HPVs have been isolated and characterised with the help of cloning systems in bacteria and more recently by PCR amplification. The molecular organisation of the HPV genomes has been defined on a comparative basis with that of the well characterised bovine papillomavirus type 1 (BPV1).

Although minor variations do occur, all HPVs genomes described have at least seven early genes, E1 to E7 and two late genes L1 and L2. In addition, an upstream regulatory region harbors the regulatory sequences which appears to control most transcriptional events of the HPV genome.

E1 and E2 genes are involved in viral replication and transcriptional control, respectively and tend to be disrupted by viral integration. E6 and E7 are involved in viral transformation. E5 has also been implicated in this process.

In the HPVs involved in cervical carcinoma such as HPV 16 and 18, the oncogenic process starts after integration of viral DNA. The integration results in the inactivation of genes coding for the capsid proteins L1 and L2 and loss of E2 repressor function leads to deregulation of the E6/E7 open reading frame installing continuously overexpression of the two early proteins E6 and E7 that will lead to gradually loss of the normal cellular differentiation and the development of the carcinoma. E6 and E7 overcome normal cell cycle by inactivating major tumor suppressor proteins, p53 and pRB, the retinoblastoma gene product, respectively.

Carcinoma of the cervix is common in women and develops through a pre-cancerous intermediate stage to the invasive carcinoma which frequently leads to death. The intermediate stages of the disease is known as cervical intraepithelial neoplasia and is graded I to III in terms of increasing severity (*CIN I-III*).

Clinically, HPV infection of the female anogenital tract manifests as cervical flat condylomas, the hallmark of which is the koilocytosis affecting predominantly the superficial and intermediate cells of the cervical squamous epithelium.

Koilocytes which are the consequence of a cytopathic effect of the virus, appear as multinucleated cells with a perinuclear clear haloe. The epithelium is thickened with abnormal keratinisation responsible for the warty appearance of the lesion.

Such flat condylomas when positive for the HPV 16 or 18 serotypes, are high-risk factors for the evolution toward cervical intraepithelial neoplasia (CIN) and carcinoma in situ (CIS) which are themselves regarded as precursor lesions of invasive cervix carcinoma.

The natural history of oncogenic HPV infection presents 3 consecutive phases, namely:

- (1) a latent infection phase,
- (2) a phase of intranuclear viral replication with product of complete virions, which corresponds to the occurrence of koilocytes. At this stage, the HPV is producing its full range of proteins including E2, E5, E6, E7, L1 and L2.
- (3) a phase of viral integration into the cellular genome, which triggers the onset of malignant transformation, and corresponds to CIN II and CIN III/CIS with progressive disappearance of koilocytes. At this stage, the expression of E2 is down-regulated, the expression of E6 and E7 is enhanced. Between CIN II/III and CIN III / Cervix carcinoma the viral DNA changes from being episomal in the basal cells to integration of E6 and E7 genes only (tumoral cells). 85% of all cervix carcinomas are squamous cell carcinomas most predominantly related to the HPV16 serotype. 10% and 5% are adenocarcinomas and adenosquamous cell carcinomas respectively, and both types are predominantly related to HPV 18 serotype. Nevertheless other oncogenic HPV's exist.

International Patent Application No. WO 96/19496 discloses variants of human papilloma virus E6 and E7 proteins, particularly fusion proteins of E6/E7 with a deletion in both the E6 and E7 proteins. These deletion fusion proteins are said to be immunogenic.

The present invention provides compositions comprising either an E6 or E7 or an E6/E7 fusion protein linked to an immunological fusion partner having T cell epitopes.

In a preferred form of the invention, the immunological fusion partner is derived from protein D of Hemophilus influenza B. Preferably the protein D derivative comprises approximately the first 1/3 of the protein, in particular approximately the first N-terminal 100-110 amino acids. The protein D may be lipidated (Lipo Protein D). Other immunological fusion partners include the non-structural protein from influenzae virus, NS1 (hemagglutinin). Typically the N terminal 81 amino acids are utilised, although different fragments may be used provided they include T-helper epitopes.

In another embodiment the immunological fusion partner is the protein known as LYTA. Preferably the C terminal portion of the molecule is used. Lyta is derived from Streptococcus pneumoniae which synthesize an N-acetyl-L-alanine amidase,

amidase LYTA, (coded by the *lytA* gene {Gene, 43 (1986) page 265-272} an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of E.coli C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at its amino terminus has been described {Biotechnology: 10, (1992) page 795-798}. As used herein a preferred embodiment utilises the repeat portion of the *LytA* molecule found in the C terminal end starting at residue 178. A particularly preferred form incorporates residues 188 - 305.

Accordingly, the present invention in preferred embodiment provides fusion proteins comprising Protein D - E6 from HPV 16, Protein D - E7 from HPV 16 Protein D - E7 from HPV 18, Protein D - E6 from HPV 18, and Protein D E6 E7 from both HPV 16 and 18. The protein D part preferably comprises the first 1/3 of protein D. It will be appreciated that other E6 and E7 proteins may be utilised from other HPV subtypes.

The proteins of the present invention preferably are expressed in *E. coli*. In a preferred embodiment the proteins are expressed with a Histidine tail comprising between 5 to 9 and preferably six Histidine residues. These are advantageous in aiding purification.

The protein E7 may in a preferred embodiment carry a mutation to reduce the binding for the *rb* site (retinoblastoma gene product) and hence eliminate any potential transforming capacity. Preferred mutations for HPV 16 E7 involve replacing Cys₂₄ with Glycine, or Glutamic acid₂₈ with Glutamine. In a preferred embodiment the E7 protein contains both these mutations.

Preferred mutations for the HPV 18 E₇ involve replacing Cys₂₇ with Glycine and/or Glutamic acid₂₉ with Glutamine. Again preferably both mutations are present.

Single or double mutations may also be introduced p53 region of E₆ to eliminate any potential transforming ability.

In a further embodiment of the invention there is provided an E6 E7 fusion protein from HPV linked to an immunological fusion partner. A preferred Immunological fusion partner is Protein D, more preferably the first 1/3 of protein D.

The present invention also provides a DNA encoding the proteins of the present invention. Such sequences can be inserted into a suitable expression vector and expressed in a suitable host.

A DNA sequence encoding the proteins of the present invention can be synthesized using standard DNA synthesis techniques, such as by enzymatic ligation as described by D.M. Roberts *et al.* in Biochemistry 1985, 24, 5090-5098, by chemical synthesis, by *in vitro* enzymatic polymerization, or by PCR technology utilising for example a heat stable polymerase, or by a combination of these techniques.

Enzymatic polymerisation of DNA may be carried out *in vitro* using a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50µl or less. Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer, such as 0.05M Tris (pH 7.4), 0.01M MgCl₂, 0.01M dithiothreitol, 1mM spermidine, 1mM ATP and 0.1mg/ml bovine serum albumin, at a temperature of 4°C to ambient, generally in a volume of 50ml or less. The chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982), or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S. Sproat, and R.C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B.S. Sproat, and W. Bannwarth, Tetrahedron Letters, 1983, 24, 5771; M.D. Matteucci and M.H. Caruthers, Tetrahedron Letters, 1980, 21, 719; M.D. Matteucci and M.H. Caruthers, Journal of the American Chemical Society, 1981, 103, 3185; S.P. Adams *et al.*, Journal of the American Chemical Society, 1983, 105, 661; N.D. Sinha, J. Biernat, J. McMannus, and H. Koester, Nucleic Acids Research, 1984, 12, 4539; and H.W.D. Matthes *et al.*, EMBO Journal, 1984, 3, 801.

The process of the invention may be performed by conventional recombinant techniques such as described in Maniatis *et al.*, Molecular Cloning - A Laboratory Manual; Cold Spring Harbor, 1982-1989.

In particular, the process may comprise the steps of :

- i) preparing a replicable or integrating expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes the protein or an immunogenic derivative thereof;
- ii) transforming a host cell with said vector;
- iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said protein; and
- iv) recovering said protein.

The term 'transforming' is used herein to mean the introduction of foreign DNA into a host cell. This can be achieved for example by transformation, transfection or infection with an appropriate plasmid or viral vector using e.g. conventional techniques as described in Genetic Engineering; Eds. S.M. Kingsman and A.J. Kingsman; Blackwell Scientific Publications; Oxford, England, 1988. The term 'transformed' or 'transformant' will hereafter apply to the resulting host cell containing and expressing the foreign gene of interest.

Preferably recombinant antigen of the invention are expressed in *E. coli*. The expression strategy include fusion of E7, E6 or E6/E7 fusion to the 1/3-N-terminal portion of protein D from *Haemophilus influenzae* B, an immunological fusion partner providing T cell helper epitopes. An affinity polyhistidine tail is engineered at the carboxy terminus of the fusion protein allowing for simplified purification. Such recombinant antigen is overexpressed in *E. coli* as insoluble protein.

Preferably the proteins of the invention are coexpressed with thioredoxin in trans (TIT). Coexpression of thioredoxin in trans versus in cis is preferred to keep antigen free of thioredoxin without the need for protease. Thioredoxin coexpression eases the solubilisation of the proteins of the invention. Thioredoxin coexpression has also a significant impact on protein purification yield, on purified-protein solubility and quality.

The expression vectors are novel and also form part of the invention.

The replicable expression vectors may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA

segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together with said linear segment encode the desired product, such as the DNA polymer encoding the protein of the invention, or derivative thereof, under ligating conditions.

5 Thus, the DNA polymer may be preformed or formed during the construction of the vector, as desired.

The choice of vector will be determined in part by the host cell, which may be prokaryotic or eukaryotic but preferably is *E. coli*. Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses.

10 The preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis *et al.* cited above.

The recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under
15 transforming conditions. Suitable transforming conditions are conventional and are described in, for example, Maniatis *et al.* cited above, or "DNA Cloning" Vol. II, D.M. Glover ed., IRL Press Ltd, 1985.

The choice of transforming conditions is determined by the host cell. Thus, a bacterial host such as *E. coli* may be treated with a solution of CaCl_2 (Cohen *et al.*,
20 Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of RbCl , MnCl_2 , potassium acetate and glycerol, and then with 3-[N-morpholino]-propane-sulphonic acid, RbCl and glycerol. Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells. The invention also extends to a host cell transformed with a replicable expression vector of
25 the invention.

Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis *et al.* and "DNA Cloning" cited above. Thus, preferably the cell is supplied with nutrient and cultured at a temperature below 50°C.

30 The product is recovered by conventional methods according to the host cell. Thus, where the host cell is bacterial, such as *E. coli* it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate.

Where the host cell is mammalian, the product may generally be isolated from the nutrient medium or from cell free extracts. Conventional protein isolation techniques include selective precipitation, adsorption chromatography, and affinity chromatography including a monoclonal antibody affinity column.

When the proteins of the present invention are expressed with a histidine tail (His tag). The proteins can easily be purified by affinity chromatography using an ion metal affinity chromatography column (IMAC) column.

A second chromatographic step, such as Q-sepharose may be utilised either before or after the IMAC column to yield highly purified protein. If the immunological fusion partner is C-LYTA, then it is possible to exploit the affinity of CLYTA for choline and/or DEAE to purify this product. Products containing both C-LYTA and his tags can be easily and efficiently purified in a two step process involving differential affinity chromatography. One step involves the affinity of the His tag to IMAC columns, the other involves the affinity of the C-terminal domain of LYTA for choline or DEAE.

Proteins comprising both a C-LYTA and Histidine tag are new and accordingly form one aspect of the invention. These may be purified to high levels (greater than 80% preferably greater than 90%) by a simple two step differential affinity procedure.

The proteins of the present invention are provided preferably at least 80% pure more preferably 90% pure as visualized by SDS PAGE. The protein present a major single band when analysed by SDS PAGE under reducing conditions, and western blot analysis show less than 5% host cell protein contamination.

The present invention also provides pharmaceutical composition comprising a protein of the present invention in a pharmaceutically acceptable excipient. A preferred vaccine composition comprises at least Protein D - E6 from HPV 16 or derivative thereof together with Protein D - E7 from HPV 16. Alternatively the E6 and E7 may be presented in a single molecule, preferably a Protein D E6/E7 fusion. Such vaccine may optionally contain either or both E6 and E7 proteins from HPV 18, preferably in the form of a Protein D - E6 or Protein D - E7 fusion protein or Protein D E6/E7 fusion protein. The vaccines of the present invention may contain other HPV antigens from HPV 16 or 18. In particular, the vaccine may contain L1 or L2

antigen monomers. Alternatively such L1 or L2 antigens may be presented together as a virus like particle or the L1 alone protein may be presented as virus like particle or capsomer structure. Such antigens, virus like particles and capsomer are per se known. See for example WO94/00152, WO94/20137, WO94/05792, & WO93/02184. Additional early proteins may be included such as E2 or preferably E5 for example. The vaccine of the present invention may additionally comprise antigens from other HPV strains, preferably from strains HPV 6 11, HPV 31 or 33.

Vaccine preparation is generally described in Vaccine Design - The subunit and adjuvant approach (Ed. Powell and Newman) Pharmaceutical Biotechnology Vol. 6 Plenum Press 1995. Encapsulation within liposomes is described by Fullerton, US Patent 4,235,877.

The proteins of the present invention are preferably adjuvanted in the vaccine formulation of the invention. Suitable adjuvants include an aluminium salt such as aluminium hydroxide gel (alum) or aluminium phosphate, but may also be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, or polyphosphazenes.

In the formulation of the inventions it is preferred that the adjuvant composition induces a preferential TH1 response. Suitable adjuvant systems include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL) together with an aluminium salt.

An enhanced system involves the combination of a monophosphoryl lipid A and a saponin derivative particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739.

A particularly potent adjuvant formulation involving QS21, 3D-MPL & tocopherol in an oil in water emulsion is described in WO 95/17210 and is a preferred formulation.

Accordingly in one embodiment of the present invention there is provided a vaccine comprising a protein D (or derivative thereof) - E6 or protein D (or derivative thereof) - E7 adjuvanted with a monophosphoryl lipid A or derivative thereof.

Preferably the vaccine additionally comprises a saponin, more preferably QS21.

Preferably the formulation additionally comprises an oil in water emulsion and tocopherol. The present invention also provides a method for producing a vaccine formulation comprising mixing a protein of the present invention together with a pharmaceutically acceptable excipient, such as 3D-MPL.

The invention will be further described by reference to the following examples:

EXAMPLE I: Construction of an *E. coli* strain expressing fusion Protein-D1/3 - E7 -His (HPV16)

1) - Construction of expression plasmid

a) - Plasmid **pMG MCS prot D1/3** (= pRIT14589) is a derivative of pMG81 (described in UK patent application n° 951 3261.9 published as WO97/01640) in which the codons 4-81 of NS1 coding region from Influenza were replaced by the codons corresponding to residues Ser 20 → Thr127 of mature protein D of Haemophilus Influenzae strain 772, biotype 2 (H. Janson *et al.*, 1991, Infection and Immunity, Jan. p.119-125). The sequence of Prot-D1/3 is followed by a multiple cloning site (11 residues) and a coding region for a C-terminal histidine tail (6 His). This plasmid is used to express the fusion protein D1/3-E7-His.

b) - HPV genomic **E6 and E7 sequences** type **HPV 16** (See Dorf *et al.*, Virology 1985, 145, p. 181-185) were amplified from HPV 16 full length genome cloned in pBR322 (obtained from Deutsches Krebsforschungszentrum (DKFZ), Referenzzentrum für human pathogen Papillomaviruses - D 69120 - Heidelberg) and were subcloned into pUC19 to give TCA 301 (= pRIT14462).

Construction of plasmid TCA 308 (= pRIT14501): a plasmid expressing the fusion Protein-D1/3-E7-His

The nucleotides sequences corresponding to amino acids 1 → 98 of E7 protein are amplified from pRIT14462. During the polymerase chain reaction, NcoI and SpeI restriction sites were generated at the 5' and 3' ends of the E7 sequences allowing insertion into the same sites of plasmid pMG MCS Prot D1/3 to give plasmid TCA308 (= pRIT14501). The insert was sequenced to verify that no modification had

been generated during the polymerase chain reaction. The sequence for the fusion protein-D1/3-E7-His (HPV 16) is described in figure 1.

2) - Transformation of AR58 strain

Plasmid pRIT14501 was introduced into *E. coli* AR58 (Mott *et al.*, 1985, Proc. Natl. Acad. Sci., 82:88) a defective λ lysogen containing a thermosensitive repressor of the λ pL promoter.

3) - Growth and induction of bacterial strain - Expression of Prot -D1/3-E7-His

Cells of AR58 transformed with plasmid pRIT14501 were grown in 100 ml of LB medium supplemented with 50 μ g/ml of Kanamycin at 30°C. During the logarithmic phase of growth bacteria were shifted to 39°C to inactivate the λ repressor and turn on the synthesis of protein D1/3-E7-His. The incubation at 39°C was continued for 4 hours. Bacteria were pelleted and stored at -20°C.

EXAMPLE II: Characterisation of fusion Protein D1/3-E7-His (HPV 16)

Frozen cells are thawed and resuspended in 10 ml of PBS buffer. Cells are broken in a French pressure cell press SLM Aminco at 20,000 psi (three passages). The extract is centrifuged at 16,000 g for 30 minutes at 4°C.

After centrifugation of extracts described above, aliquots of supernatant and pellet were analysed by SDS-polyacrylamide gel electrophoresis and Western blotting. A major band of about 33 kDa, localised in the pellet fraction, was visualised by Coomassie stained gels and identified in Western blots by rabbit polyclonal anti-protein-D and by Ni-NTA conjugate coupled to calf intestinal alkaline phosphatase (Qiagen cat. n° 34510) which detects accessible histidine tail. The level of expression represents about 5 % of total protein as shown on a Coomassie-stained SDS-polyacrylamide gel.

EXAMPLE III: Protein -D1/3-E7-His (HPV 16) Purification

One litre culture of bacteria expressing protein -D1/3-E7-His, is centrifuged at 11,300 g for 30 min at 4°C and cell pellet is kept at -80°C until further treatment. After resuspension in 75 ml PBS buffer, *E. coli* cells are broken in a French pressure cell press (SLM Aminco®) at 20,000 psi. Lysed cells are pelleted by centrifugation at 17,000g for 30 minutes. Pellet, containing the protein-D1/3-E7-His, is washed once in 30 ml of 2M NaCl, 50mM Phosphate pH 7.5, then twice in 30 ml 50mM

Phosphate pH 7.5. Proteins are solubilised after 2 hours incubation of the

pellet in 30 ml of 8 M urea, 50 mM phosphate pH 7.5 at RT. Cells debris are eliminated by 15 min centrifugation at 17,000 g, 4°C. Protein purification is carried out at RT°, 15 ml of solubilised protein are applied onto a 5 ml Ni2+NTA (Qiagen) resin (Pharmacia column XK 16/20) preequilibrated in 8M urea, 50 mM phosphate pH 7.5 at a flow rate of 0.2 ml/min. The column is washed in the same buffer until the absorbance at 280 nm reaches the base line. The protein is eluted with a 0-600 mM Imidazole gradient in 8M urea, 50 mM phosphate pH 7.5. The flow rate of these two last steps is brought to 1 ml/min. Eluted fractions are analysed by SDS polyacrylamide gel electrophoresis and by Western blotting. ProtD1/3-E7-His, visualised by Coomassie blue staining, by a polyclonal anti protein D or by a monoclonal anti E7 antibody, appears as a major single band at about 32 kDalton and is estimated as a 95% pure protein. No E. coli contaminants, traced with a polyclonal anti E. coli proteins antibody, are observed.

In order to eliminate urea, 9 ml of purified antigen, at 1.33 mg/ml (Bradford), is dialysed against 3 litres of PBS buffer overnight at RT° followed by a 4 hours dialysis against a fresh PBS buffer. 80% of urea free protein is recovered as soluble protein. To eliminate contaminating endotoxins, 6 ml of dialysed protein are incubated with 1 ml of Affiprep polymyxin gel (Biorad), for 3 hours at 4°C under gentle stirring. A second incubation with 500 µl of Affiprep polymyxin resin is performed to minimise the endotoxin level to 8.8 EU/µg protein. After sterile filtration on a 0.22 µm filter device (Millex 0.22 GV, Millipore), prot-D1/3-E7-His at 0.665 mg/ml is assayed for stability. SDS PAGE analysis showed no evolution of the protein after 7 days incubation at - 20°C, 4°C, RT° or 37°C.

EXAMPLE IV: Construction of an *E.coli* strain expressing fusion Protein-D1/3-E6-his / HPV16

1. Construction of expression plasmid

a) Plasmid pMG MCS prot D1/3 (= pRIT14589) is a derivative of pMG81 (described in WO97/01640 in which the codons 4-81 of NS1 coding region from Influenza were replaced by the codons corresponding to residues Ser 20 → Thr 127 of mature protein D of Haemophilus Influenzae strain 772, biotype 2 (H. Janson *et al.*, 1991, Infection and Immunity, Jan. p.119-125). The sequence of Prot-D1/3 is followed by a multiple

cloning site (11 residues) and a coding region for a C-terminal histidine tail (6 His).

This plasmid is used to express the fusion protein D1/3-E6-his.

- b) HPV genomic E6 and E7 sequences type HPV16 (Seedorf *et al.*, Virology 1985, 145, p.181-185) were amplified from HPV16 full length genome cloned in pBR322 (obtained from Deutsches Krebsforschungszentrum (DKFZ), Referenzzentrum für human pathogen Papillomaviruses - c) D 69120 - Heidelberg) and were subcloned into pUC19 to give TCA 301 (= pRIT14462).

Construction of plasmid TCA 307 (=pRIT14497) : a plasmid expressing the fusion Protein-D1/3-E6-His /HPV16

The nucleotides sequences corresponding to amino acid.

1 → 151 of E6 protein were amplified from pRIT14462. During the polymerase chain reaction, NcoI and SpeI restriction sites were generated at the 5' and 3' ends of the E6 sequences allowing insertion into the same sites of plasmid pMGMS Prot D1/3 to give plasmid TCA307 (= pRIT14497) (see figure 2). The insert was sequenced to verify that no modification had been generated during the polymerase chain reaction. The coding sequence for the fusion protein-D1/3-E6-His is described in figure 3.

2. Transformation of AR58 strain

Plasmid pRIT14497 was introduced into *E. coli* AR58 (Mott *et al.*, 1985, Proc. Natl. Acad. Sci., 82:88) a defective λ lysogen containing a thermosensitive repressor of the λ pL promoter.

3. Growth and induction of bacterial strain - Expression of Prot-D1/3-E6-His

Cells of AR58 transformed with plasmid pRIT14497 were grown in 100 ml of LB medium supplemented with 50 μ g/ml of Kanamycin at 30°C. During the logarithmic phase of growth bacteria were shifted to 39°C to inactivate the λ repressor and turn on the synthesis of protein D1/3-E6-his. The incubation at 39°C was continued for 4 hours. Bacteria were pelleted and stored at -20°C.

4. Characterization of fusion Protein D1/3-E6-his (HPV 16)

Preparation of extracts

Frozen cells are thawed and resuspended in 10 ml of PBS buffer. Cells are broken in a French pressure cell press SLM Aminco at 20,000 psi (three passages). The extract is centrifuged at 16,000 g for 30 minutes at 4°C.

Analysis on Coomassie-stained SDS-polyacrylamide gels and Western blots

5 After centrifugation of extracts described above, aliquots of supernatant and pellet were analysed by SDS-polyacrylamide gel electrophoresis and Western blotting.

A major band of about 32 kDa, localized in the pellet fraction, was visualised by Coomassie stained gels and identified in Western blots by rabbit polyclonal anti-protein-D and by Ni-NTA conjugate coupled to calf intestinal alkaline phosphatase (Qiagen cat. n° 34510) which detects accessible histidine tail. The level of expression represents about 5 % of total protein.

5. Coexpression with thioredoxin

In an analogous fashion to the expression of prot D 1/3 E7 His from HPV 18 (example XIII) an *E.coli* strain AR58 was transformed with a plasmid encoding thioredoxin and protein D 1/3 E7 His (HPV 16).

EXAMPLE V: Purification of Prot D 1/3 E6 His (HPV 16)

HPV-16 ProtD1/3 E6 recombinant antigen was expressed in *E. coli* (AR58). Expression strategy included fusion of E6 to the 1/3-N-terminal portion of protein D from *Haemophilus influenzae*, an immunological fusion partner providing T cell helper epitopes. An affinity polyhistidine tail was engineered at the carboxy terminus of the fusion protein. The recombinant antigen was overexpressed in *E. coli* as insoluble proteins.

Solubilisation of the antigen required denaturing agents. In absence of denaturing agent, ProtD1/3-E6-His precipitated at neutral pH. To circumvent the solubility problems, co-expression of these proteins with Thioredoxin in Trans (TIT), a folding partner was carried out.

Bacterial expressions are conducted in LB media in presence of 0.05 mg/ml of kanamycin at 30°C plus 0.2 mg/ml of Ampicillin when Thioredoxin is coexpressed. Recombinant protein expression is thermally induced by transferring the cells to 42°C, when cell optical density (OD_{600 nm}) of 0.4 is reached. Protein expression is

maintained for 4 hours. Purification was carried out according to the following protocol.

Cell Culture Pellet	60 OD ₆₀₀ 1 mM pefabloc, 2M NaCl, PBS pH 7.4 (Buffer A)
French Press Disruptor	Three passes 20,000 psi
Centrifugation	17,000g 30 min, 4°C
Pellet Washes	2M NaCl, PBS pH 7.4 (Buffer B) x1 PBS pH 7.4 (Buffer C) x2
Centrifugation	17,000g 30 min, 4°C
Pellet Solubilisation	6 M Guanidine Chloride, 20 mM PO ₄ , pH 7.0 (Buffer D) Overnight at 4°C
Centrifugation	17,000g 30 min, 4°C
Supernatant on IMAC	Equilibration : 6 M Guanidine Chloride, 20 mM PO ₄ , pH 7.0 (Buffer D) Elution: Imidazole steps (0.025M, 0.1M, 0.5M) in 8M Urea, 20 mM PO ₄ , pH 7.0
Affiprep Polymyxin	8M Urea, 20 mM PO ₄ , pH 7.0 (Buffer E) 2h RT°
Dialysis	4M Urea, 0.5 M Arginine, 150 mM NaCl, 10 mM PO ₄ , pH 6.8 (Buffer I) 2M Urea, 0.5 M Arginine, 150 mM NaCl, 10 mM PO ₄ pH 6.8, (Buffer J) 0M Urea, 0.5 M Arginine, 150 mM NaCl, 10 mM PO ₄ pH 6.8 (Buffer K)

Cells are efficiently broken by high-pressure homogenisation using a French
 5 pressure cell device. Antigen is extracted with high concentration of protein
 denaturant. This first step breaks open the bacterial cell wall and antigen is extracted
 from the bacterial insoluble fraction. The following purification was carried out on 4
 liter culture.

BUFFERS

A. PBS / 2M NaCl / 1 mM Pefabloc

5 B. PBS / 2 M NaCl

C. PBS: 137 mM NaCl, 2.7 mM KCl, 8.1 mM NaH₂PO₄, 1.47 mM KH₂PO₄ pH 7.4.

10 D. 6 M Guanidium Chloride, 20 mM PO₄ (NaH₂PO₄ (2 H₂O) / K₂HPO₄ (3 H₂O))
pH 7.0

Starting material is 10 flasks of 400 ml culture each.

Cell paste is suspended to 60 OD₆₀₀ in Buffer A (240 ml of Buffer A in this case), prior cell lysis by three passes through a French press disruptor (20,000 psi).

15 Lysed cells are pelleted 30 min at 15,000 g at 4° C. Bacterial cell pellet containing the recombinant protein is washed once in 240 ml Buffer B, then twice in 240 ml Buffer C.

Prot D E6-His (TIT) is solubilised by 240 ml Buffer D overnight at 4° C on a rotating wheel. Cell debris are pelleted 30 min at 15,000 g at 4° C. Supernatant (230
20 ml) is stored at -20° C. The material is then subjected to IMAC chromatography.

The chelating ligand NTA (nitrilo-tri-acetic-acid) is attached to an Agarose support (Qiagen). NTA ligand is charged with nickel metal ion with which it interacts through 4 of the 6 coordination sites of the nickel. The two remaining coordination sites of nickel interact strongly with histidine residues of the 6xHis-tagged protein.

25 Elution is achieved by competition with Imidazole which bind to the Ni-NTA and displace the tagged antigen.

Ni-NTA Agarose Qiagen (catalogue number: 30 250) was used.

SOLUTIONS

30 D : 6 M Guanidium Chloride, 20 mM PO₄ (NaH₂PO₄ (2H₂O)/K₂HPO₄ (3H₂O)),
pH 7.0

E : 8M Urea, 20 mM PO₄ (NaH₂PO₄ (2H₂O)/K₂HPO₄ (3H₂O)), pH 7.0

35 F : E + 0.025 M Imidazole

G : E + 0.1 M Imidazole

40 H : E + 0.5 M Imidazole

0.5 M NaOH

Deionized water

5 0.02% NaN_3

PURIFICATION

- 10 a) The resin (15 ml resin/ 230 ml sample) is packed and equilibrated in 10 column volumes (C.V.) of Buffer D at 15 cm h^{-1} .
- b) Supernatant from solubilised fraction is injected onto the column at 15 cm h^{-1}
- c) Column is washed at 15 cm h^{-1} with buffer D until OD 280 nm returns to the baseline.
- 15 d) Column is washed with 2 CV of Buffer E at 15 cm h^{-1} . The wash fraction is recovered.
- e) Column is first eluted with 5 CV of Buffer F. Elimination of 25 kD major contaminant.
- f) Column is then eluted with 2 CV of Buffer G.
- 20 g) Column is finally eluted with 3 CV of Buffer H. Elution of the antigen.
- Antigen positive fractions are pooled (30 ml).

Endotoxin is removed by affiprep chromatography.

Affi-Prep® Polymyxin support consists of USP Grade Polymyxin B coupled to the Affi-Prep® Matrix. Due to its high affinity to the lipid A moiety of endotoxins, 25 polymyxin B binds endotoxin molecules with high capacity and selectivity.

SOLUTIONS

E : 8M Urea, 20 mM PO_4 (NaH_2PO_4 ($2\text{H}_2\text{O}$)/ K_2HPO_4 ($3\text{H}_2\text{O}$)), pH 7.0 (apyrogenic).

0.5 M Na OH

30 Deionized apyrogenic water

PROCEDURE

- 1) Affi-Prep® Polymyxin resin is washed in 10 volumes of 0.1 M NaOH, followed by 10 volumes of pyrogen free water.
- 2) Resin is equilibrated in 10 volumes of Buffer E.
- 35 3) 15 ml (half-pool) of IMAC-eluted sample is incubated with 3 ml of Affi-Prep® Polymyxin resin in a batch mode.

- 4) Incubation is pursued 4 hours at Room Temperature or O/N at 4°C on a rotating wheel.
- 5) Sample is centrifuged 10 min at 2000 g (Beckman GS-6R).
- 6) Supernatant containing the antigen is collected and submitted to endotoxins and protein assays.
- 7) Resin is discarded.

Small molecules diffuse through a semi-permeable membrane while large molecules are retained. The process of dialysis is driven by the difference in concentration of the solutes on the two sides of the membrane. New buffer solution is introduced until buffer composition on each side equalises.

BUFFERS

- I** : 4M Urea, 0.5 M Arginine, 0.15M NaCl, 10 mM PO₄ (NaH₂PO₄ (2H₂O)/K₂HPO₄ (3H₂O)) pH 6.8
- J** : 2M Urea, 0.5 M Arginine, 0.15M NaCl, 10 mM PO₄ (NaH₂PO₄ (2H₂O)/K₂HPO₄ (3H₂O)) pH 6.8
- K** : 0M Urea, 0.5 M Arginine, 0.15M NaCl, 10 mM PO₄ (NaH₂PO₄ (2H₂O)/K₂HPO₄ (3H₂O)) pH 6.8

- 1) The Sample (15 ml) is introduced into a dialysis tubing (20.4 mm diameter and 6 cm height).
- 2) Dialysis tubing is placed in a 2 liters cylinder containing Buffer I under stirring at 4°C for 2 hours.
- 3) Dialysis tubing is placed in a 2 liters cylinder (under stirring) containing Buffer J ; at 4°C for 2 hours.
- 4) Dialysis tubing is placed in a 2 liters cylinder containing Buffer K (under stirring) at 4°C O/N. Buffer is changed and dialysis is pursued 2 more hours at 4°C.

Millipore Sterile Millex-GV 0.22µ, 13 mm. Catalogue number : SLGV0130S.

All steps are performed at room temperature (RT ~ 22°C), the antigen appears stable.

Antigen solution is filtered through a 0.2 µm filter to prevent any bacterial growth. Antigen is kept at -20°C in Nunc vials.

CHARACTERISATION:

Protein D1/3 E6 His is characterised as follows:

ProteinD1/3-E6-His is a 273 amino acids long peptide with 112 amino acids coming from Protein D part. ProteinD1/3-E6-His has a theoretical Molecular Weight- of 32 kD and migrates on SDS-PAGE as a 33 kD protein. ProteinD1/3-E6-His
5 theoretical isoelectric point is 8.17.

The viral Protein E6 is a basic protein containing 14 cystein residues, eight of them (Cys 30,33,63,66 and Cys 103,106,136,139) are involved in two C-terminal zinc binding motifs.

Protein D 1/3-E6-His is expressed as insoluble protein, in E. coli-AR 58 strain,
10 with Thioredoxin in Trans, a folding partner. Cell culture is produced in 400 ml flask.
5.4 mg of 95 % pure protein is obtained per liter of culture.

EXAMPLE VI: Construction of an *E. coli* strain expressing fusion Protein-D1/3-E6E7-his / HPV16

1. Construction of expression plasmid

- 15 a) Plasmid pMG MCS prot D1/3 (= pRIT14589) is a derivative of pMG81 (described Supra) in which the codons 4-81 of NS1 coding region from Influenza were replaced by the codons corresponding to residues Ser 20 → Thr 127 of mature protein D of Haemophilus Influenzae strain 772, biotype 2 (H. Janson *et al.*, 1991, Infection and Immunity, Jan. p.119-125). The sequence of Prot-D1/3 is followed by a multiple
20 cloning site (11 residues) and a coding region for a C-terminal histidine tail (6 His). This plasmid is used to express the fusion protein D1/3-E6E7-his.
- b) HPV genomic E6 and E7 sequences type HPV16 (Seedorf *et al.*, Virology 1985, 145, p.181-185) were amplified from HPV16 full length genome cloned in pBR322 (obtained from Deutsches Krebsforschungszentrum (DKFZ), Referenzzentrum für
25 human pathogen Papillomaviruses - D 69120 - Heidelberg) and were subcloned into pUC19 to give TCA 301 (= pRIT14462).
- c) The coding sequences for E6 and E7 in TCA301 (= pRIT
14462) were modified with a synthetic oligonucleotides adaptor (inserted between Afl
III and Nsi I sites) introducing a deletion of 5 nucleotides between E6 and E7 genes
30 to remove the stop codon of E6 and create fused E6 and E7 coding sequences in the plasmid TCA309(= pRIT 14556) see figure 4.

Construction of plasmid TCA 311(= pRIT14512) : a plasmid expressing the fusion Protein-D1/3-E6E7-His /HPV16

The nucleotides sequences corresponding to amino acids 1 → 249 of fused E6E7 protein were amplified from pRIT14556. During the polymerase chain reaction, NcoI and SpeI restriction sites were generated at the 5' and 3' ends of the E6E7 fused sequences allowing insertion into the same sites of plasmid pMGMCSProt D1/3 to give plasmid TCA311 (= pRIT14512) (see figure 5). The insert was sequenced to verify that no modification had been generated during the polymerase chain reaction. The coding sequence for the fusion protein-D1/3-His is described figure 6.

2. Transformation of AR58 strain

Plasmid pRIT14512 was introduced into *E. coli* AR58 (Mott et al., 1985, Proc. Natl. Acad. Sci., 82:88) a defective λ lysogen containing a thermosensitive repressor of the λ pL promoter.

3. Growth and induction of bacterial strain - Expression of Prot-D1/3-E6E7-His

Cells of AR58 transformed with plasmid pRIT14512 were grown in 100 ml of LB medium supplemented with 50 μ g/ml of Kanamycin at 30°C. During the logarithmic phase of growth bacteria were shifted to 39°C to inactivate the λ repressor and turn on the synthesis of protein D1/3-E6E7-his. The incubation at 39°C was continued for 4 hours. Bacteria were pelleted and stored at -20°C.

4. Characterization of fusion Protein D1/3-E6E7-his

Frozen cells are thawed and resuspended in 10 ml of PBS buffer. Cells are broken in a French pressure cell press SLM Aminco at 20.000 psi (three passages). The extract is centrifuged at 16.000 g for 30 minutes at 4°C.

After centrifugation of extracts described above, aliquots of supernatant and pellet were analysed by SDS-polyacrylamide gel electrophoresis and Western blotting.

A major band of about 48 kDa, localized in the pellet fraction, was visualised by Coomassie stained gels and identified in Western blots by rabbit polyclonal anti-protein-D and by Ni-NTA conjugate coupled to calf intestinal alkaline phosphatase (Qiagen cat. n° 34510) which detects accessible histidine tail. The level of expression represents about 1 % of total protein.

EXAMPLE: Vib

In an analogous fashion the fusion protein of Lipo D 1/3 and E6-E7 from HPV16 was expressed in *E.coli* in the presence of thioredoxin.

The N-terminal of the pre-protein (388 aa) contains MDP residues followed by 16 amino acids of signal peptide of lipoprotein D (from *Haemophilus Influenzae*) which is cleaved in vivo to give the mature protein (370 aa). Lipoprotein portion (aa 1 to 127) is followed by the proteins E6 and E7 in fusion. The C terminal of the protein is elongated by TSGHHHHHH.

The protein was purified by the following protocol:

EXAMPLE VII: Lipoprotein D1/3-E6-E7-His (TIT) Purification**A) SOLUBILISATION.**

Cell paste is suspended to 60 OD₆₀₀ in 2 M NaCl, 20 mM Phosphate (NaH₂PO₄/K₂HPO₄) pH 7.5 in presence of 1 mM Pefabloc as protease inhibitor prior cell lysis by three passes through a French press disruptor (20,000 psi). Lysed cells are pelleted 30 min at 15,000 g at 4°C. In order to reduce endotoxin level, bacterial cell pellet containing the recombinant protein is washed twice in 4 M urea, 2 M NaCl, 20 mM Phosphate pH 7.5, once in 2% Empigen BB, 20 mM Phosphate pH 7.5 and finally twice in 20 mM Phosphate buffer pH 7.0 to eliminate trace of detergent (each wash is performed in the same volume used for cell suspension). LipoProt.D1/3-E6-E7-His (TIT) is solubilised (in the same volume used for cell suspension) by 8 M urea in 0.2 M βMercaptoEthanol (= βMeOH), 20 mM PO₄ pH 12 overnight at 4 °C followed by a two hours incubation at RT° versus the same buffer. Cell debris are pelleted 30 min at 15,000 g at 4°C. Supernatant is kept at -20°C.

B) PURIFICATION**1) Anion exchange chromatography on Q-Sepharose fast flow.**

225 ml of frozen sample is thawed at room temperature in a cold water bath and is applied onto a Q-Sepharose fast flow column (Pharmacia, XK 26/20) preequilibrated in 8 M urea, 0.2 M βMeOH, 20 mM PO₄ pH 12 (30 ml resin/ 225 ml supernatant) at 45 cm/h. Column is washed by 8 M urea, 0.2 M βMeOH, 20 mM PO₄ pH 12, until OD 280 nm reaches the baseline, followed by a second wash in 8 M urea, 20 mM Phosphate pH 12 (in 2 column volumes) Elution is performed by NaCl

steps (0.1 M, 0.25 M, 0.5 M NaCl, each step in about 2 column volumes) in 8 M urea, 20 mM Phosphate pH 12, at 45 cm/h. 0.5 M NaCl-eluted fractions are pooled.

2) Ion Metal Affinity Chromatography (IMAC).

0.5 M NaCl-eluted fractions from Q Sepharose step are pooled and dialyzed versus 0.2 M NaCl, 8 M urea, 20 mM Phosphate pH 10 before loading onto a Ni²⁺-NTA (Qiagen) column (XK 26/20, Pharmacia) preequilibrated in 8 M urea, 20 mM PO₄ pH 12 (30 ml resin/ 61 ml sample) at 5.6 cm/h. Column is washed in 8 M urea, 20 mM PO₄ pH 12 until the base line is reached then by 8 M urea, 20 mM PO₄ pH 10. Antigen is eluted by Imidazole steps (0.025 M, 0.05 M, 0.1 M, 0.15 M, 0.2 M, 0.5 M Imidazole, each step in two column volumes) in 8 M urea, 20 mM PO₄ pH 10, at 45 cm/h. 0.05 M Imidazole-eluted fractions are pooled.

C) CONCENTRATION.

Imac sample is concentrated about 5 times (to 0.407 mg/ml) on a 5 kDa Filtron Omega membrane in a stirred cell from AMICON at RT°.

D) DIALYSIS

Concentrated sample is dialyzed at RT versus decreasing-urea-concentration steps (4 M, 2 M urea) in 0.5 M Arginine, 150 mM NaCl, 10 mM PO₄ pH 6.8. Last dialysis against 0.5 M Arginine, 150 mM NaCl, 10 mM PO₄ pH 6.8 is achieved at 4°C.

RESULTS:

IMAC step is able to eliminate a 32 kD contaminant at 0.025 M Imidazole which eluted also some antigen. 0.05 M Imidazole-eluted Antigen is estimated pure at 90 % by Coomassie blue staining of SDS-PAGE. After these two purification steps, sample is free of E. coli contaminants. Western blotting analysis using specific antigen-N and/or C terminus antibodies shows a heterogeneous pattern of bands with higher and lower MW than the full length protein. This pattern suggests the presence of aggregates and incompletely processed protein and/or degraded one, copurified with the full length protein.

EXAMPLE VIII: Construction of E.coli strain B1002 expressing fusion ProtD1/3-E7

Mutated (cys24->gly,glu26->gln) type HPV16

1)-Construction of expression plasmid

Starting material:

- a) - Plasmid pRIT 14501 (= TCA 308) which codes for fusion ProtD1/3-E7 -His
 - b) - Plasmid LITMUS 28 (New England Biolabs cat n° 306-28) , a cloning vector pUC-derived
 - c) - Plasmid pMG MCS ProtD1/3 (pRIT 14589) , a derivative of pMG81 (described Supra) in which the codons 4-81 of NS1 coding region from Influenza were replaced by the codons corresponding to residues Ser 20 → Thr 127 of mature protein D of Haemophilus Influenzae strain 772, biotype 2 (H. Janson *et al.*, 1991, Infection and Immunity, Jan. p.119-125). The sequence of Prot-D1/3 is followed by a multiple cloning site (11 residues) and a coding region for a C-terminal histidine tail (6 His)
- 10 **Construction of plasmid pRIT 14733(=TCA347): a plasmid expressing the fusion Protein-D1/3-E7 mutated (cys24->gly ,glu26->gln) with His tail**

- The NcoI - XbaI fragment from pRIT 14501 (=TCA 308) , bearing the coding sequence of E7 gene from HPV16 , elongated with an His tail , was subcloned in an intermediate vector Litmus 28 useful for mutagenesis to give pRIT 14909 (=TCA337)
- 15 Double mutations **cys24->gly** (Edmonds and Vousden , J.Virology 63 : 2650 (1989) and **glu26->gln** (Phelps et al , J.Virology 66: 2418-27 (1992) were chosen to impair the binding to the antioncogene product of Retinoblastome gene (pRB). The introduction of mutations in E7 gene was realized with the kit " Quick Change Site directed Mutagenesis (Stratagene cat n° 200518) to give plasmid pRIT
- 20 14681(=TCA343) .After verification of presence of mutations and integrity of the complete E7 gene by sequencing , the mutated E7 gene was introduced into vector pRIT 14589 (= pMG MCS ProtD1/3) to give plasmid pRIT 14733 (=TCA347) (Figure 7).

- The sequence for the fusion protein-D1/3-E 7 mutated (cys24->gly, glu26->gln) -His is described in the figure 8.
- 25

2)-Construction of strain B1002 expressing ProtD1/3-E7mutated (cys 24->gly , glu26->gln)-His /HPV16

- Plasmid pRIT 14733 was introduced into *E.coli* AR58 (Mott et al. ,1985, Proc. Natl. Acad. Sci. , 82:88) a defective λ lysogen containing a thermosensitive repressor of the λ pL promoter ,to give strain B1002 , by selection for transformants resistant to kanamycine
- 30

3)-Growth and induction of bacterial strain B1002 - Expression of ProtD1/3-E7 mutated (cys 24->gly , glu26->gln)-His /HPV16

Cells of AR58 transformed with plasmid pRIT 14733 (B1002 strain) were grown at 30°C in 100 ml of LB medium supplemented with 50 µgr /ml of Kanamycin. During the logarithmic phase of growth bacteria were shifted to 39°C to inactivate the λ repressor and turn on the synthesis of ProtD1/3-E7 mutated -His /HPV16 . The incubation at 39°C was continued for 4 hours . Bacteria were pelleted and stored at -20°C.

4)-Characterization of fusion ProtD1/3-E7 mut (cys24->gly, glu26->gln)- His type HPV16.


Frozen cells were thawed and resuspended in 10 ml of PBS buffer. Cells were broken in a French Pressure cell press SLM Aminco at 20 000 psi (three passages) . The extract was centrifuged at 16000 g for 30 minutes at 4°C.

After centrifugation of extracts described above, aliquots of supernatant and pellet were analysed by SDS-polyacrylamide gel electrophoresis and Western blotting.

A major band of about 33 kDa, localized in the pellet fraction, was visualised by Coomassie stained gels and identified in Western blots by rabbit polyclonal 22 J 70 anti-protein D, by monoclonal anti E7 /HPV16 from Zymed and by Ni-NTA conjugate coupled to calf intestinal alkaline phosphatase (Qiagen cat. n° 34510) which detects accessible histidine tail. The level of expression represents about 3 to 5 % of total protein.

Cells of B1002 were separated from the culture broth by centrifugation. The concentrated cells of B1002 were stored at -65°C.

EXAMPLE IX: Purification PROTD1/3 E7 (Dmutant) HPV 16

GENERAL PURIFICATION SCHEME - HPV 16 E 7

a) Preparation of cell suspension

The frozen concentrated cells of B1002 were thawed and resuspended in a cell disruption buffer at +4°C (see table 1) to a final optical density OD₆₅₀ of 60 (corresponding to a cell concentration of approximately 25 g DCW L⁻¹).

b) Cell disruption

The cells were disrupted by two passes at 1000 bar through a high-pressure homogeniser (Rannie). The broken cell suspension was collected in a flask maintained at 4°C.

- 10 CELL DISRUPTION BUFFER: Na₂HPO₄ (0.02N), NaCl (2M) pH adjusted to 7.5 with HCl 3N (Merck)

Purification

2a) Dynamic membrane filtration (DMF®-PALL FILTRON)

- 2 Litres of broken cell suspension (OD 60) is loaded on the DMF®, a dynamic
 15 filtration system from PALL, mounted with a 0.2µm cut-off membrane.
 concentration from 2 Litres to 1L to give *sample PCC1*
 washing at constant volume with 3 volumes (3L) of empigen-EDTA buffer
 (concentration EDTA 1.86g, Empigen (30%) 3.33mL, PO₄³⁻ 0.5M 40.00mL
 40.00mL) gave *sample PD1*
 20 concentration from 1L to 300mL gave *sample PCC2*
 washing at constant volume with 10volumes (3L) of empigen buffer
 (concentration L⁻¹: Empigen 30%, 3.33mL, PO₄³⁻ 0.5M 40mL) pH 7.5 gave *sample*
 solubilisation of the protein in by addition of the same volume (300 mL) of
 Guanidine hydrochloride 8M buffer (concentration L⁻¹ Gu.HCl 764g;
 25 Empigen 30% 3.33mL, PO₄³⁻ 0.5M 40mL) pH 7.5
 recovery of the protein: Collection of the permeate - *sample P3* during
 Concentration to initial volume (300 mL) and
 Diafiltration with 3 volume of Guanidine hydrochloride 4M buffer
 (concentration L⁻¹: Gu.HCl 328.12g, Empigen (30%) 3.33mL PO₄³⁻ 0.5M
 30 40.00mL) pH 7.5.
 All these steps are made in a cold room (2-8°C), pH adjusted with 0.5M
 PO₄³⁻.

The P3 fraction is store at -20°C waiting for the next purification step.

2b) Zn-chelating sepharose chromatography

The P3 fraction is thawed and injected in a packed and equilibrated Zn-
 5 chelating sepharose FF .

After that, the column is:

Washed with around 3 volumes of Guanidine hydrochloride 4M buffer (see
 above) - *sample Zn-FT*

Washed with around 5 volumes of Urea 4M buffer (concentration L⁻¹: Urea
 10 240.24g Empigen 3.33mL PO₄³⁻ 0.5M 40.00mL) - *sample Zn-W*

Eluted with around 3volumes of Urea 4M-Imidazole 20mM buffer
 (concentration L⁻¹ Urea 240.24g, Empigen (30%) 3.33mL Imidazole (1.36g) PO₄³⁻
 0.5M 40.00mL pH 7.5) buffer as above, but concentration L⁻¹ of Imidazole 34.04g -
sample Zn-20

15 Eluted with Urea 4M-Imidazole 500mM to the end of the UV peak - *sample*
Zn-500

The column is the washed with EDTA 50mM and NaOH 0.5M.
 Zn chelating sepharose eluate (Zn-500) is stored between 2-8°C before the next
 purification step.

20 The Zn-chelating sepharose chromatography operations are carried out at
 room temperature.

2c) Q-sepharose chromatography

The Zn-500 fraction is injected in a packed and equilibrated Q-sepharose
 25 FF .

After that, the column is:

Washed with around 7 volumes of Urea 4M buffer (see above) - *sample*
QS-FT

Washed with around 10 volumes of Urea 4M buffer without empigen
 30 (concentration L⁻¹ Urea 240.24g PO₄³⁻ 0.5M 40.00 mL) - *sample QS-W1*

Washed with around 10 volumes of Urea 6M buffer without empigen (Urea
 360.36g/L) - *sample QS-W2*

Eluted with around 5 volumes of Urea 6M-NaCl 200mM buffer
 (concentration L⁻¹: Urea 360.36g NaCl 11.69g, 40.00 mL PO₄³⁻).

Eluted with around 3 volumes of Urea 6M-NaCl 500mM buffer (as above, but NaCl 29.22g/L). The exact end of the fraction is determined by the end of the UV peak.- *sample QS-500*

Eluted with 4 volumes of Urea 4M-NaCl 1M buffer (concentration L^{-1} Urea 360.36, NaCl 58.44 g 40.00 mL $PO_4^{3-}(0.5)$ - *sample QS-1M*

The column is then washed with NaOH 0.5M

QS-sepharose eluate (QS-500) is stored between 2-8°C before the next purification step.

The Q-sepharose chromatography operations are carried out at room temperature.

2d) Ultrafiltration

The QS-500 fraction is then treated on a 10kD ultrafiltration unit (Ultrasette - Pall Filtron)

The product is first concentrated to around 1mg /mL of protein and then diafiltrated against 10 volumes of phosphate buffer.

The permeate (fraction UF-P) is discarded and the retentate (fraction UF-R) is stored at 2-8°C waiting for final filtration.

Ultrafiltration operations are carried out at 2-8°C

2e) Final filtration

The final bulk (UF-R fraction) is filtered through a 0.22µm sterile filter (Millipak-Millipore) under laminar flow and in an aseptic class 100 room.

The final concentration is between 0.5 and 1.0 µg/mL.

The sterile bulk is stored at -20°C.

EXAMPLE X: Construction of an *E. coli* strain expressing fusion clyta-E6-his (HPV 16)

1. Construction of expression plasmid

a) -Plasmid pRIT14497 (= TCA307), that codes for fusion ProtD1/3-E6-His /HPV16

b) -Plasmid pRIT14661 (= DVA2), an intermediate vector containing the coding sequence for the 117 C-terminal codons of LytA of Streptococcus Pneumoniae. LytA is derived from Streptococcus pneumoniae which synthesize an N-acetyl-L-alanine amidase, amidase LYTA, (coded by the *lytA* gene {Gene, 43 (1986) pag 265-272} an autolysin that specifically degrades certain bonds in the peptidoglycan backbone .

The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE.

1.b Construction of plasmid pRIT14634 (=TCA332): a plasmid expressing the fusion clyta-E6-His /HPV16

5 a) The first step was the purification of the large NcoI-AflIII restriction fragment from plasmid pRIT14497 and the purification of the small AflII-AflIII restriction fragment from pRIT14661

b) The second step was linking of clyta sequences to the E7-His sequences (NcoI and AflIII are compatible restriction sites) that gave rise to the plasmid pRIT 14634 (=TCA332), coding for the fusion protein clyta-E6-His under the control of the pL promoter. (see figure 9)

The coding sequence for the fusion protein clyta-E6-His is described in figure 10.

Transformation of AR58 strain

Plasmid pRIT14634 was introduced into *E. coli* AR58 (Mott et al., 1985, Proc. Natl. Acad. Sci., 82:88) a defective λ lysogen containing a thermosensitive repressor of the λ pL promoter.

Growth and induction of bacterial strain - Expression of clyta-E6-His

Cells of AR58 transformed with plasmid pRIT14634 were grown in 100 ml of LB medium supplemented with 50 μ g/ml of Kanamycin at 30°C. During the logarithmic phase of growth bacteria were shifted to 39°C to inactivate the λ repressor and turn on the synthesis of protein clyta-E6-his. The incubation at 39°C was continued for 4 hours. Bacteria were pelleted and stored at -20°C.

4. Characterization of fusion clyta-E6-his

Frozen cells were thawed and resuspended in 10 ml of PBS buffer. Cells were broken in a French pressure cell press SLM Aminco at 20.000 psi (three passages). The extract was centrifuged at 16.000 g for 30 minutes at 4°C. After centrifugation of extracts described above, aliquots of supernatant and pellet were analysed by SDS-polyacrylamide gel electrophoresis and Western blotting.

A major band of about 33 kDa, localized in the pellet fraction, was visualised by Coomassie stained gels and identified in Western blots by rabbit polyclonal anti-clyta antibodies and by Ni-NTA conjugate coupled to calf intestinal alkaline phosphatase

(Qiagen cat. n° 34510) which detects accessible histidine tail. The level of expression represents about 3 % of total protein.

EXAMPLE XI: Construction of an *E. coli* strain expressing fusion clyta-E7-his (HPV 16)

1. Construction of expression plasmid

1.a Starting materials

- a) -Plasmid pRIT14501 (= TCA308), that codes for fusion ProtD1/3-E7-His /HPV16
- b)-Plasmid pRIT14661 (= DVA2), an intermediate vector containing the coding sequence for the 117 C-terminal codons of LytA of *Streptococcus Pneumoniae*.

1.b Construction of plasmid pRIT14626 (=TCA330): a plasmid expressing the fusion clyta-E7-His / HPV16

- a) The first step was the purification of the large NcoI-AflIII restriction fragment from plasmid pRIT14501 and the purification of the small AflIII-AflIII restriction fragment from pRIT14661

- b) The second step was linking of clyta sequences to the E7-His sequences (NcoI and AflIII are compatible restriction sites)that gave rise to the plasmid pRIT 14626 (=TCA330), coding for the fusion protein clyta-E7-His under the control of the pL promoter.
(Figure 11)

The coding sequence for the fusion protein clyta-E7-His is described in figure 12.

2. Transformation of AR58 strain

Plasmid pRIT14626 was introduced into *E. coli* AR58 (Mott et al., 1985, Proc. Natl. Acad. Sci., 82:88) a defective λ lysogen containing a thermosensitive repressor of the λ pL promoter.

3. Growth and induction of bacterial strain - Expression of clyta-E7-His

Cells of AR58 transformed with plasmid pRIT14626 were grown in 100 ml of LB medium supplemented with 50 μ gr/ml of Kanamycin at 30°C. During the logarithmic phase of growth bacteria were shifted to 39°C to inactivate the λ repressor and turn on the synthesis of protein clyta-E7-his. The incubation at 39°C was continued for 4 hours. Bacteria were pelleted and stored at -20°C.

4. Characterization of fusion clyta-E7-his

Frozen cells were thawed and resuspended in 10 ml of PBS buffer. Cells were broken in a French pressure cell press SLM Aminco at 20.000 psi (three passages). The extract was centrifuged at 16.000 g for 30 minutes at 4°C. After centrifugation of extracts described above, aliquots of supernatant and pellet were analysed by SDS-polyacrylamide gel electrophoresis and Western blotting.

A major band of about 35 kDa, localized in the pellet fraction, was visualised by Coomassie stained gels and identified in Western blots by rabbit polyclonal anti-clyta antibodies and by Ni-NTA conjugate coupled to calf intestinal alkaline phosphatase (Qiagen cat. n° 34510) which detects accessible histidine tail. The level of expression represents about 5 % of total protein.

EXAMPLE XII: Construction of an *E. coli* strain expressing fusion clyta-E6E7-his (HPV 16)

1. Construction of expression plasmid

1.a Starting materials

a) -Plasmid pRIT14512 (= TCA311), that codes for fusion ProtD1/3-E6E7-His /HPV16

b)-Plasmid pRIT14661 (= DVA2), an intermediate vector containing the coding sequence for the 117 C-terminal codons of LytA of *Streptococcus Pneumoniae*.

1.b Construction of plasmid pRIT14629 (=TCA331): a plasmid expressing the fusion clyta-E6E7-His /HPV16

a)The first step was the purification of the large NcoI-AflIII restriction fragment from plasmid pRIT14512 and the purification of the small AflII-AflIII restriction fragment from pRIT14661

b)The second step was linking of clyta sequences to the E7-His sequences (NcoI and AflIII are compatible restriction sites)that gave rise to the plasmid pRIT 14629 (=TCA331), coding for the fusion protein clyta-E6E7-His under the control of the pL promoter. (see figure 13)

The coding sequence for the fusion protein clyta-E6E7-His is described in figure 14.

2. Transformation of AR58 strain

Plasmid pRIT14629 was introduced into *E. coli* AR58 (Mott et al., 1985, Proc. Natl. Acad. Sci., 82:88) a defective λ lysogen containing a thermosensitive repressor of the λ pL promoter.

3. Growth and induction of bacterial strain - Expression of clyta-E6E7-His

Cells of AR58 transformed with plasmid pRIT14629 were grown in 100 ml of LB medium supplemented with 50 μ g/ml of Kanamycin at 30°C. During the logarithmic phase of growth bacteria were shifted to 39°C to inactivate the λ repressor and turn on the synthesis of protein clyta-E6E7-his. The incubation at 39°C was continued for 4 hours. Bacteria were pelleted and stored at -20°C.

4. Characterization of fusion clyta-E6E7-his

Frozen cells were thawed and resuspended in 10 ml of PBS buffer. Cells were broken in a French pressure cell press SLM Aminco at 20.000 psi (three passages). The extract was centrifuged at 16.000 g for 30 minutes at 4°C.

After centrifugation of extracts described above, aliquots of supernatant and pellet were analysed by SDS-polyacrylamide gel electrophoresis and Western blotting.

A major band of about 48 kDa, localized in the pellet fraction, was visualised by Coomassie stained gels and identified in Western blots by rabbit polyclonal anti-clyta antibodies and by Ni-NTA conjugate coupled to calf intestinal alkaline phosphatase (Qiagen cat. n° 34510) which detects accessible histidine tail. The level of expression represents about 1 % of total protein.

EXAMPLE XIII: Prot D1/3 E7 his (HPV 18) (E.Coli B1011)

Protein D1/3 E7 his HPV expressed with Thioredoxin inTrans (E.Coli B1012)

1) - Construction of expression plasmids

1).a.Construction of plasmid TCA316(=pRIT 14532) a plasmid expressing the fusion Protein-D1/3-E7-His /HPV18

Starting materials

a) - Plasmid pMG MCS prot D1/3 (= pRIT14589) is a derivative of pMG81 (described in UK patent application n° 951 3261.9 published as WO97/01640 in which the codons 4-81 of NS1 coding region from Influenza were replaced by the codons corresponding to residues Ser 20 \rightarrow Thr 127 of mature protein D of Haemophilus Influenzae strain 772, biotype 2 (H. Janson *et al.*, 1991, Infection and

Immunity, Jan. p.119-125). The sequence of Prot-D1/3 is followed by a multiple cloning site (11 residues) and a coding region for a C-terminal histidine tail (6 His) (see figure 15). This plasmid is used to express the fusion protein D1/3-E7-his.

- b) - HPV genomic E6 and E7 sequences of prototype HPV18(Cole et al., J.Mol.Biol.(1987)193,599-608) were amplified from HPV16 full length genome cloned in pBR322 (obtained from Deutsche Krebsforschungszentrum (DKFZ), Referenzzentrum für human pathogen Papillomaviruses - D 69120 - Heidelberg) and were subcloned into pUC19 to give TCA 302 (= pRIT14467).

Construction of plasmid TCA 316(= pRIT14532)

- The nucleotides sequences corresponding to amino acids 1 → 105 of E7 protein were amplified from pRIT14467. During the polymerase chain reaction, NcoI and SpeI restriction sites were generated at the 5' and 3' ends of the E7 sequences allowing insertion into the same sites of plasmid pMGMCs Prot D1/3 to give plasmid TCA316 (= pRIT14532). The insert was sequenced and a modification versus E7/HPV18 prototype sequence was identified in E7 gene (nucleotide 128 G→A) generating a substitution of a glycine by a glutamic acid (aa 43 in E7, position 156 in fusion protein). The sequence for the fusion protein-D1/3-E7-His /HPV18 is described in figure 16.

1).b. Construction of plasmid TCA313 (=pRIT14523): a plasmid

- expressing thioredoxin**

Starting materials

- a) - Plasmid pBBR1MCS4(Antoine R. and C.Locht, Mol.Microbiol. 1992,6,1785-1799 ; M.E.Kovach et al. Biotechniques 16, (5), 800-802) which is compatible with plasmids containing ColE1 or P15a origins of replication.
- b) - Plasmid pMG42 (described in WO93/04175) containing the sequence of promoter pL of Lambda phage
- c) - Plasmid pTRX (Invitrogen, kit Thiofusion K350-01) bearing the coding sequence for thioredoxin followed by AspA transcription terminator.

Construction of plasmid TCA313(=pRIT14523)

- The fragment EcoRI-NdeI fragment from pMG42, bearing pL promoter and the NdeI-HindIII fragment from pTRX, bearing the coding sequence for thioredoxin

followed by AspA terminator, were purified and ligated into the EcoRI and HindIII sites of plasmid vector pBBR1MCS4 to give plasmid TCA313(= pRIT14523) (see figure 17).

The sequence for thioredoxin is described in figure 18.

2) - Transformation of AR58 strain

2).a. To obtain strain B1011 expressing ProtD1/3-E7-His/HPV18

Plasmid pRIT14532 was introduced into *E. coli* AR58 (Mott et al., 1985, Proc. Natl. Acad. Sci., 82:88) a defective λ lysogen containing a thermosensitive repressor of the λ pL promoter, by selection for transformants resistant to kanamycine.

2).b. Construction of strain B1012 expressing ProtD1/3-E7-His/HPV18 and thioredoxin

Plasmid pRIT14532 and pRIT14523 were introduced into *E. coli* AR58 (Mott et al., 1985, Proc. Natl. Acad. Sci., 82:88) a defective λ lysogen containing a thermosensitive repressor of the λ pL promoter, by double selection for transformants resistant to kanamycin and ampicillin.

3) - Growth and induction of bacterial strains B1011 and B1012 - Expression of Prot-D1/3-E7-His/HPV18 without and with thioredoxin in trans

Cells of AR58 transformed with plasmids pRIT14532 (B1011 strain) and Cells of AR58 transformed with plasmids pRIT14532 and pRIT14523 (B1012 strain) were grown at 30°C in 100 ml of LB medium supplemented with 50 µg/ml of Kanamycin for B1011 strain and supplemented 50 µg/ml of Kanamycin and 100 µg/ml of Ampicillin for B1012 strain. During the logarithmic phase of growth bacteria were shifted to 39°C to inactivate the λ repressor and turn on the synthesis of protein D1/3-E7-his/HPV18 and thioredoxin. The incubation at 39°C was continued for 4 hours. Bacteria were pelleted and stored at -20°C.

Characterization of fusion Protein D1/3-E7-his /HPV18

Preparation of extracts

Frozen cells are thawed and resuspended in 10 ml of PBS buffer. Cells are broken in a French pressure cell press SLM Aminco at 20.000 psi (three passages).

The extract is centrifuged at 16.000 g for 30 minutes at 4°C.

Analysis on Coomassie-stained SDS-polyacrylamide gels and Western blots

After centrifugation of extracts described above, aliquots of supernatant and pellet were analysed by SDS-polyacrylamide gel electrophoresis and Western blotting.

The fusion protD1/3-E7-His (about 31 kDa) was visualised by Coomassie stained gels in the pellet fraction for strain B1011 and partially localized (30%) in the supernatant fraction for strain B1012 and was identified in Western blots by rabbit polyclonal anti-protein-D and by Ni-NTA conjugate coupled to calf intestinal alkaline phosphatase (Qiagen cat. n° 34510) which detects accessible histidine tail. The level of expression represents about 1-3% of total protein as shown on a Coomassie-stained SDS-polyacrylamide gel.

For the extract of strain B1012 the thioredoxin (about 12 KDa) was visualised by coomassie stained gel in the supernatant and identified in western blots by monoclonal anti thioredoxin (Invitrogen R920-25)

Purification of Prot D1/3 E7-his/HPV18

Recombinant HPV 18-ProtD 1/3-E7-His is expressed in E. coli (as described above) AR58 strain. All steps are performed at room temperature (RT \approx 22°C). Proteins are followed by monitoring OD_{280 nm}. Between steps, antigens positive fractions are kept at -20°C.

Purified antigen is stable one week at -20°C and 4°C (no degradation) but appears more susceptible to oxidation after incubation at 37°C.

d) - Solubility

Protein solubility is pH dependent (see below) with decrease of solubility for pH<7.4:

	PBS pH 7.4	686 μ g/ml	100%
25	PBS pH 7.2	560 μ g/ml	81%
	PBS pH 7.0	498 μ g/ml	72%
	PBS pH 6.8	327 μ g/ml	48%

e) - The HPV 18 Prot D1/3 E7 protein is composed of 227 amino acids. Its theoretical molecular weight is 25.9 kDa, and a theoretical isoelectric point of 5.83. It migrates at about 31.5 kDa in reducing SDS PAGE.

EXAMPLE XIV: Purification of HPV 18 Protein D1/3 E7

a) - Solubilisation

Cell paste is suspended to 60 OD₆₀₀ in 2 M NaCl, 20 mM Phosphate.

(NaH₂PO₄/K₂HPO₄) pH 7.6 prior cell lysis by two passes through a Rannie disruptor. Lysed cells are pelleted 30 min at 9,000 rpm in a JA 10 rotor at 4°C. In order to reduce endotoxin level, bacterial cell pellet containing the recombinant protein is washed once in 5 mM EDTA, 2 M NaCl, PBS pH 7.4; once in 4 M urea, 20 mM Phosphate pH 7.4 and finally once in PBS pH 7.4 to eliminate trace of EDTA (each wash is performed in twice volume used for cell suspension). HPV18-Prot.D1/3-E7-His (TIT for Thioredoxin In Trans) is solubilised (in the same volume used for cell suspension) by 6 M Guanidine-Chloride, 50 mM PO₄ pH 7.6 overnight at 4 °C. Cell debris are pelleted 30 min at 9,000 rpm in a JA 10 rotor at 4°C. Supernatant is supplemented with 0.5% Empigen BB and incubated 30 min at RT.

b) - Purification

1).a.Immobilized Metal Affinity Chromatography

125.ml of sample are loaded onto a Zn²⁺-Chelating Sepharose FF column (XK 26/20, Pharmacia; 50 ml gel/ 125 ml solubilisation) preequilibrated in 0.5% Empigen BB, 6 M Guanidine-Chloride, 50 mM PO₄ pH 7.6 at 4 ml/min. Column is washed by Guanidine Chloride 6M, PO₄ 50 mM pH 7.6 until the base line is reached then by 6 M urea, 0.5 M NaCl, 50 mM PO₄ pH 7.6. Antigen is eluted by 0.25 M-Imidazole in 6 M urea, 0.5 M NaCl, 50 mM PO₄ pH 7.6, at 2 ml/min (Fig. 1B). IMAC-eluted sample is dialyzed at 4°C versus PBS pH 7.4

1).b. Affi-Prep[®] Polymixin (Bio-Rad)

To reduce endotoxin level, 28 mg (37 ml) of antigen are incubated in batch mode with 2 ml of Affiprep Polymyxin resin prequilibrated in PBS pH 7.4, over night at room temperature. Protein recovery is estimate at 60% and endotoxin content is reduced 6.5 times.

1).c. Analysis

Purified antigen analyzed on reducing-SDS-PAGE presents a major 30 kDa band with a second one at 55 kDa, after Coomassie Blue or Silver Staining. In a non reducing SDS-PAGE, HPV-18-ProtD1/3-E7-His appears mainly like a smear with Molecular Weight ≥ 175 kDa. However this oxidation can be reversed by addition of 5 mM of β-Mercapto-Ethanol. This pattern is confirmed by anti ProtD or by anti His Western Blotting analysis.

c) - Stability

Purified antigen is stable one week at -20°C and 4°C (no degradation) but appears more susceptible to oxidation after incubation at 37°C.

d) - Solubility

5 Protein solubility is pH dependent (see below) with decrease of solubility for pH < 7.4:

PBS pH 7.4	686 µg/ml	100%
PBS pH 7.2	560 µg/ml	81%
PBS pH 7.0	498 µg/ml	72%
PBS pH 6.8	327 µg/ml	48%

10 HPV18-ProtD1/3-E7-His protein is composed of 227 amino acids. Its theoretical molecular weight is 25.9 kDa. It migrates at about 31.5 kDa in reducing SDS-PAGE. Theoretical isoelectric point is 5.83.

EXAMPLE XV: Construction of E.coli strain B1098 expressing fusion ProtD1/3-E7

15 **Mutated (cys27->gly,glu29->gln) type HPV18**

1)-Construction of expression plasmid

Starting material:

- a) - Plasmid pRIT 14532 (= TCA 316) which codes for fusion ProtD1/3-E7 -His
 - b) - Plasmid LITMUS 28 (New England Biolabs cat n° 306-28) , a cloning vector
 - 20 pUC-derived
 - c) - Plasmid pMG MCS ProtD1/3 (pRIT 14589) , a derivative of pMG81 (described supra) in which the codons 4-81 of NS1 coding region from Influenza were replaced by the codons corresponding to residues Ser 20 → Thr 127 of mature protein D of Haemophilus Influenzae strain 772, biotype 2 (H. Janson *et al.*, 1991, Infection and
 - 25 Immunity, Jan. p.119-125). The sequence of Prot-D1/3 is followed by a multiple cloning site (11 residues) and a coding region for a C-terminal histidine tail (6 His)
- Construction of plasmid pRIT 14831(=TCA355): a plasmid expressing the fusion Protein-D1/3-E7 mutated (cys27->gly ,glu29->gln) with His tail**

The NcoI - XbaI fragment from pRIT 14532 (=TCA 316) , bearing the coding
 30 sequence of E7 gene from HPV18 , elongated with an IHis tail , was subcloned in an intermediate vector Litmus 28 useful for mutagenesis to give pRIT 14910 (=TCA348)
 By analogy with E7/HPV16 mutagenesis, double mutations cys27->gly and

glu29-->gln were chosen to impair the binding to the antioncogene product of Retinoblastome gene (pRB).

The introduction of mutations in E7 gene was realized with the kit " Quick Change Site directed Mutagenesis (Stratagene cat n° 200518) .As the sequencing of pRIT14532 had pointed out the presence of a glutamic acid in position 43 of E7 instead of a glycine in the prototype sequence of HPV18 , a second cycle of mutagenesis was realized to introduce a glycine in position 43 . We obtained plasmid pRIT 14829 (= TCA353). After verification of presence of mutations and integrity of the complete E7 gene by sequencing , the mutated E7 gene was introduced into vector pRIT 14589 (= pMG MCS ProtD1/3) to give plasmid pRIT 14831 (=TCA355) (see figure 17).

The sequence for the fusion protein-D1/3-E 7 mutated (cys27->gly, glu29->gln) -His is described in the figure 18.

2)Construction of strain B1098 expressing ProtD1/3-E7mutated (cys 27-->gly , glu29-->gln)-His /HPV18

Plasmid pRIT 14831 was introduced into *E.coli* AR58 (Mott et al. ,1985, Proc. Natl. Acad. Sci. , 82:88) a defective λ lysogen containing a thermosensitive repressor of the λ pL promoter ,to give strain B1098 , by selection for transformants resistant to kanamycin.

3)-Growth and induction of bacterial strain B1098 - Expression of ProtD1/3-E7 mutated (cys 27->gly , glu29->gln)-His /HPV18

Cells of AR58 transformed with plasmid pRIT 14831 (B1098 strain) were grown at 30°C in 100 ml of LB medium supplemented with 50 μ g /ml of Kanamycin. During the logarithmic phase of growth bacteria were shifted to 39°C to inactivate the λ repressor and turn on the synthesis of ProtD1/3-E7 mutated -His /HPV18 . The incubation at 39°C was continued for 4 hours. Bacteria were pelleted and stored at - 20°C.

4)-Characterization of fusion ProtD1/3-E7 mut (cys24->gly, glu26->gln)- His type HPV16

Frozen cells were thawed and resuspended in 10 ml of PBS buffer. Cells were broken in a French Pressure cell press SLM Aminco at 20 000 psi (three passages) . The extract was centrifuged at 16000 g for 30 minutes at 4°C.

Analysis on Coomassie stained SDS-polyacrylamide gels and Western blots

After centrifugation of extracts described above, aliquots of supernatant and pellet were analysed by SDS-polyacrylamide gel electrophoresis and Western blotting.

A major band of about 31 kDa, localized in the pellet fraction, was visualised by

- 5 Coomassie stained gels and identified in Western blots by rabbit polyclonal 22 J 70 anti-protein D and by monoclonal Penta-His (Qiagen cat. n° 34660) which detects accessible histidine tail. The level of expression represents about 3 to 5 % of total protein.

EXAMPLE XVI: Construction of an *E. coli* strain expressing fusion Protein-**10 D1/3-E6-his / HPV18****1. Construction of expression plasmid**

- a) Plasmid pMG MCS prot D1/3 (= pRIT14589) is a derivative of pMG81 (described supra) in which the codons 4-81 of NS1 coding region from Influenza were replaced by the codons corresponding to residues Ser 20 → Thr 127 of mature protein D of
- 15 Haemophilus Influenzae strain 772, biotype 2 (H. Janson *et al.*, 1991, Infection and Immunity, Jan. p.119-125). The sequence of Prot-D1/3 is followed by a multiple cloning site (11 residues) and a coding region for a C-terminal histidine tail (6 His). This plasmid is used to express the fusion protein D1/3-E6-his.

- HPV genomic E6 and E7 sequences type HPV18 (Cole *et al.*, J. Mol. Biol. 1987, 193, p.599-608.) were amplified from HPV18 full length genome cloned in pBR322 (obtained from Deutsches Krebsforschungszentrum (DKFZ), Referenzzentrum für human pathogen Papillomaviruses - D 69120 - Heidelberg) and were subcloned into pUC19 to give TCA 302 (= pRIT14467).
- 20

- Construction of plasmid TCA 314(= pRIT14526) : a plasmid expressing the**
- 25 **fusion Protein-D1/3-E6-His /HPV18**

The nucleotides sequences corresponding to amino acids

- 1 → 158 of E6 protein were amplified from pRIT14467. During the polymerase chain reaction, NcoI and SpeI restriction sites were generated at the 5' and 3' ends of the E6 sequences allowing insertion into the same sites of plasmid
- 30 pMG MCS Prot D1/3 to give plasmid TCA314 (= pRIT14526) (see figure 21). The insert was sequenced to verify that no modification had been generated during the

polymerase chain reaction. The coding sequence for the fusion protein-D1/3-E6-His is described in figure 22.

Transformation of AR58 strain

Plasmid pRIT14526 was introduced into *E. coli* AR58 (Mott et al., 1985, Proc. Natl. Acad. Sci., 82:88) a defective λ lysogen containing a thermosensitive repressor of the λ pL promoter.

3. Growth and induction of bacterial strain - Expression of Prot-D1/3-E6-His

Cells of AR58 transformed with plasmid pRIT14526 were grown in 100 ml of LB medium supplemented with 50 μ g/ml of Kanamycin at 30°C. During the logarithmic phase of growth bacteria were shifted to 39°C to inactivate the λ repressor and turn on the synthesis of protein D1/3-E6-his. The incubation at 39°C was continued for 4 hours. Bacteria were pelleted and stored at -20°C.

4. Characterization of fusion Protein D1/3-E6-his

Frozen cells are thawed and resuspended in 10 ml of PBS buffer. Cells are broken in a French pressure cell press SLM Aminco at 20.000 psi (three passages). The extract is centrifuged at 16.000 g for 30 minutes at 4°C. After centrifugation of extracts described above, aliquots of supernatant and pellet were analysed by SDS-polyacrylamide gel electrophoresis and Western blotting.

A major band of about 32 kDa, localized in the pellet fraction, was visualised by Coomassie stained gels and identified in Western blots by rabbit polyclonal anti-protein-D and by Ni-NTA conjugate coupled to calf intestinal alkaline phosphatase (Qiagen cat. n° 34510) which detects accessible histidine tail. The level of expression represents about 3-5 % of total protein.

EXAMPLE XVII: Construction of an *E. coli* strain expressing fusion Protein-

D1/3-E6E7-his / HPV18

I. Construction of expression plasmid

a) Plasmid pMG MCS prot D1/3 (= pRIT14589) is a derivative of pMG81 (described supra) in which the codons 4-81 of NS1 coding region from Influenza were replaced by the codons corresponding to residues Ser 20 \rightarrow Thr 127 of mature protein D of Haemophilus Influenzae strain 772, biotype 2 (H. Janson *et al.*, 1991, Infection and Immunity, Jan. p.119-125). The sequence of Prot-D1/3 is followed by a multiple

cloning site (11 residues) and a coding region for a C-terminal histidine tail (6 His).

This plasmid is used to express the fusion protein D1/3-E6E7-his.

b) HPV genomic E6 and E7 sequences type HPV18 (Cole et al., J.Mol.Biol. 1987, 193, 599-608) were amplified from HPV18 full length genome cloned in pBR322

(obtained from Deutsches Krebsforschungszentrum (DKFZ), Referenzzentrum für human pathogen Papillomaviruses - D 69120 - Heidelberg) and were subcloned into pUC19 to give TCA 302 (= pRIT14467).

c) The coding sequences for E6 and E7 in TCA302 (= pRIT

14467) were modified with a synthetic oligonucleotides adaptor (inserted between

Hga I and Nsi I sites) introducing a deletion of 11 nucleotides between E6 and E7 genes, removing the stop codon of E6 and creating fused E6 and E7 coding sequences in the plasmid TCA320(= pRIT 14618) see figure 23.

Construction of plasmid TCA 328(= pRIT14567) : a plasmid expressing the fusion Protein-D1/3-E6E7-His /HPV18

The nucleotides sequences corresponding to amino acids

1 → 263 of fused E6E7 protein were amplified from pRIT14618. During the polymerase chain reaction, NcoI and SpeI restriction sites were generated at the 5' and 3' ends of the E6E7 fused sequences allowing insertion into the same sites of plasmid pMGMS Prot D1/3 to give plasmid TCA328 (= pRIT14567) (see figure 24). The

insert was sequenced to verify that no modification had been generated during the polymerase chain reaction. The coding sequence for the fusion protein-D1/3-E6E7-His is described in figure 25.

2. Transformation of AR58 strain

Plasmid pRIT14567 was introduced into *E. coli* AR58 (Mott et al., 1985, Proc.

Natl. Acad. Sci., 82:88) a defective λ lysogen containing a thermosensitive repressor of the λ pL promoter.

3. Growth and induction of bacterial strain - Expression of Prot-D1/3-E6E7-His

Cells of AR58 transformed with plasmid pRIT14512 were grown in 100 ml of LB medium supplemented with 50 μ g/ml of Kanamycin at 30°C. During the logarithmic phase of growth bacteria were shifted to 39°C to inactivate the λ repressor and turn on the synthesis of protein D1/3-E6E7-his. The incubation at 39°C was continued for 4 hours. Bacteria were pelleted and stored at -20°C.

4.Characterization of fusion Protein D1/3-E6E7-his

Frozen cells are thawed and resuspended in 10 ml of PBS buffer. Cells are broken in a French pressure cell press SLM Aminco at 20.000 psi (three passages). The -- extract is centrifuged at 16.000 g for 30 minutes at 4°C.

- 5 After centrifugation of extracts described above, aliquots of supernatant and pellet were analysed by SDS-polyacrylamide gel electrophoresis and Western blotting. A major band of about 48 kDa, localized in the pellet fraction, was visualised by Coomassie stained gels and identified in Western blots by rabbit polyclonal anti-protein-D and by Ni-NTA conjugate coupled to calf intestinal alkaline phosphatase
10 (Qiagen cat. n° 34510) which detects accessible histidine tail. The level of expression represents about 1 % of total protein.

EXAMPLE XVIII: Vaccine Formulations

- Vaccines are formulated with a Protein from the above examples expressed in E. coli from the strain AR58, and as adjuvant, the formulation comprising a mixture
15 of 3 de -O-acylated monophosphoryl lipid A (3D-MPL) and aluminium hydroxide or 3D-MPL and/or QS21 optionally in an oil/water emulsion, and optionally formulated with cholesterol.

3D-MPL: is a chemically detoxified form of the lipopolysaccharide (LPS) of the Gram-negative bacteria Salmonella minnesota.

- 20 Experiments performed at Smith Kline Beecham Biologicals have shown that 3D-MPL combined with various vehicles strongly enhances both the humoral and a TH1 type of cellular immunity.

- QS21:** is one saponin purified from a crude extract of the bark of the Quillaja Saponaria Molina tree, which has a strong adjuvant activity: it activates both antigen-
25 specific lymphoproliferation and CTLs to several antigens.

Vaccine containing an antigen of the invention containing 3D-MPL and alum may be prepared in analogous manner to that described in WO93/19780 or 92/16231.

- Experiments performed at Smith Kline Beecham Biologicals have demonstrated a clear synergistic effect of combinations of 3D-MPL and QS21 in the
30 induction of both humoral and TH1 type cellular immune responses. Vaccines containing an antigen such antigens are described in US 5750110.

The oil/water emulsion is composed of 2 oils (a tocopherol and squalene), and of PBS containing Tween 80 as emulsifier. The emulsion comprised 5% squalene 5% tocopherol 0.4% Tween 80 and had an average particle size of 180 nm and is known as SB62 (see WO 95/17210).

Experiments performed at Smith Kline Beecham Biologicals have proven that the adjunction of this O/W emulsion to MPL/QS21 further increases their immunostimulant properties.

Preparation of emulsion SB62 (2 fold concentrate)

Tween 80 is dissolved in phosphate buffered saline (PBS) to give a 2% solution in the PBS. To provide 100 ml two fold concentrate emulsion 5g of DL alpha tocopherol and 5ml of squalene are vortexed to mix thoroughly. 90ml of PBS/Tween solution is added and mixed thoroughly. The resulting emulsion is then passed through a syringe and finally microfluidised by using an M110S microfluidics machine. The resulting oil droplets have a size of approximately 180 nm.

Preparation of Prot.D1/3 E7 QS21/3D MPL oil in water formulation

ProtD1/3-E7 (5µg) was diluted in 10 fold concentrated PBS pH 6.8 and H₂O before consecutive addition of SB62, 3 D MPL (5µg), QS21 (5µg) and 50 µg/ml thiomersal as preservative at 5 min interval. The emulsion volume is equal to 50% of the total volume (50µl for a dose of 100µl). All incubations were carried out at room temperature with agitation. The adjuvants controls without antigen were prepared by replacing the protein by PBS.

Tumour Regression Experiments (HPV 16) with PROT D E7

Vaccine antigen: fusion protein ProtD E7

Protein D is a lipoprotein exposed on the surface of the Gram-negative bacteria *Haemophilus influenzae*.

The inclusion of the 109 first residues of the protein D as fusion partner is incorporated to provide the vaccine antigen with bystander help properties. The antigen was formulated with QS21 3D-MPL and SB62 as described supra.

EXAMPLE XIX: *In vivo* Tumour Regression Experiments

Tumour cell line TC1:

Primary lung epithelial cells from C57BL/6 mice were immortalised by HPV 16 E6 and E7 and then transformed with an activated ras oncogene, producing a tumourigenic cell line expressing E6 and E7 (Lin KY *et al.* 1996). The E7 expression has been verified by FACS analysis of fixed and permeabilised TC1 cells using the mouse anti-HPV 16 E7 Mab (Triton Corp. Alameda, CA)

Tumour growth:

TC1 cells growing *in vitro* culture were trypsinised, washed two times in serum-free medium and were injected S.C. in the right flank of the mice. To assess treatment of established tumours, TC1 cells were injected at a dose of 3 X 10⁴ cells/mouse. One and two weeks after the tumour cell injection, mice were vaccinated with 5 µg in 100 µl of protD 1/3 E7 His intra foot pad (50 µl / foot pad) in PBS or in the 3D-MPL, QS21 and SB62 or with PBS or with the adjuvant alone. Five C57BL/6 mice (Iffa Credo) were used in each group. Mice were monitored twice a week for tumour growth. The mean tumour mass/group is shown in figure 26, the mice vaccinated with protD 1/3 E7 His in PBS or with PBS or the adjuvant alone developed progressively growing tumours (0-1 tumour-free animal/group). On the contrary, four out of five mice vaccinated with protD1/3 E7 His in adjuvant did not develop a tumour, one animal developed a very small and stable tumour at day 40. This results indicate that the protein protD1/3 E7 His from HPV 16 formulated in adjuvant is able to induce the regression of small established tumours expressing this antigen.

Immunological read out

Proliferation assay:

For *in vitro* assay, Lymphocytes were prepared by crushing the spleen or the popliteal lymph nodes from the vaccinated mice at day 69. An aliquot of 2 X 10⁵ cells was plated in triplicate in 96 well plates with decreasing concentrations (10, 1, 0.1 µg/ml) of protD 1/3 E7 His coated or not onto latex microbeads (Sigma) to restimulate the cells *in vitro* (72 Hrs). T cell proliferation was measured by 3H thymidine incorporation.

Figure 27 and 28 compares the ability of protD E7 to stimulate the proliferation of splenocytes and lymph node cells primed *in vivo* either by PBS, 3D-MPL, QS21 SB62, ProtD1/3 E7 His and ProtD1/3 E7 His + the adjuvant of 3D-MPL,

QS21, SB62 and shows that high proliferative responses in spleen were detected only in mice immunised with protD1/3 E7 His in adjuvant compared to the other groups.

Antibody response

Individual serum were taken at the same time as the organs were taken and submitted to indirect ELISAs.

5 $5\mu\text{g/ml}$ of purified E7 protein was used as coated antigen. After saturation in PBS + 1% newborn calf serum 1 Hr at 37°C , the sera were serially diluted (starting at 1/100) in the saturation buffer and incubated O/N at 4°C or 90min at 37°C . After washing in PBS Tween 20 0.1%, biotinylated goat Anti mouse Ig (1/1000) or goat anti mouse Ig subclass (total IgG, IgG1, IgG2a, IgG2b) antisera (1/5000) were used as second antibodies , after an incubation of 90 min at 37°C , streptavidin coupled to peroxidase was added and TMB (tetra-methyl-benzidine / peroxide) was used as substrate, after 10 min. the reaction was stopped with H_2SO_4 0.5 M and the O.D.450 was determined.

The subclass-specific anti E7 titers elicited by the vaccinations in the different groups of mice are shown in Figure 29 as a comparison of the relative mean midpoint dilution of the serum.

These results show that a weak antibody response is triggered with 2 injections of ProtD 1/3 E7 HPV16 alone.

Much more anti-E7 antibodies are generated when ProtD1/3 E7 was injected in the presence of the adjuvant SB62, QS21 + 3D-MPL.

No IgA nor IgM were detected in any of the serum samples even in the serum of the mice that received ProtD 1/3 E7 in the adjuvant SB62, QS21 + 3D-MPL (data not shown) On the contrary, the total IgG level was slightly increased by the vaccination of the mice with ProtD 1/3 E7 alone and was greatly increased by the addition of the adjuvant SB62, QS21 + 3D-MPL to the protein. The analysis of the concentrations of the different IgG subclass show that a mixed antibody response has been induced as the concentration of all types of IgG subclass analyzed (IgG1, IgG2a, and IgG2b) were increased in the serum of the mice that received the adjuvanted antigen, compared to the concentration observed in the serum of mice that received the antigen or the adjuvant alone. The predominant isotype found was IgG2b which

represented more than 80% of the total of IgG), this isotype is generally said to be associated with the induction of a TH1 type immune response.

EXAMPLE XX: *In vivo* Tumour Protection Experiments

Mice were immunised 2 times at 14 days interval with either PBS, adjuvant of example 1, 5 µg of protD1/3 E7 His or 5 µg of protD1/3 E7 His in the adjuvant of example 1 intra foot pad in a volume of 100 µl (50 µl/foot pad).

Tumour growth:

Four weeks after the latest vaccination mice were challenged with 2X10⁵ TC1 cells/mouse S.C. in the flank. TC1 cells growing *in vitro* culture, were trypsinised and washed two times in serum-free medium and injected. 5 mice used in each group were monitored twice a week for tumour growth.

Figure 30 shows that vaccination with the E7 protein in the SB62 QS21, 3D-MPL adjuvant protect the mice against the development of tumour (only one animal/5 has a very small and stable tumour) in all the other groups, that received the E7 protein without the adjuvant or the adjuvant alone developed growing tumours.

Immunological read out

Three weeks after the latest vaccination, before the tumour challenge 5 mice in each group were sacrificed for immunological read out.

Proliferation assay

For *in vitro* assay, Lymphocytes were prepared as described above from the spleen and from the popliteal draining lymph nodes. An aliquot of 2 X 10⁵ cells was plated in triplicate in 96 well plates with decreasing concentrations (10, 1, 0.1 µg/ml) of protD 1/3 E7 His coated or not onto latex microbeads (Sigma) to restimulate the cells *in vitro* (72 Hrs). T cell proliferation was measured by 3H thymidine incorporation.

Figure 31 and 32 show respectively that, both with splenocytes or popliteal lymph node cells, as it was observed in the therapeutic settings, a better lymphoproliferative activity was obtained for the mice that received the E7 protein in the SB62 QS21, 3D-MPL adjuvant **antibody response**.

Figure 33 shows that as in the therapeutic settings, a better antibody response was observed in the serum of mice vaccinated with the ProtD1/3 E7 protein

formulated in the 3D-MPL, QS21 O/W adjuvant. A mixed antibody response was triggered, as all the IgG subclass tested (IgG 2a, IgG2b, IgG1), in this case also, IgG2b was the predominant isotype found, representing 75% of the total IgG.

EXAMPLE XXI: Vaccination experiments with Prot D1/3 E7 (HPV 18)

Mice were vaccinated twice, 2 weeks apart, with 5 µg in 100 µl of protD 1/3 18 E7 His intra foot pad (50 µl / foot pad) in PBS or QS21, 3D-MPL and SB62, DQ MPL as described in WO96/33739 or DQ alum MPL as described in WO98/15827. Eight 6-8 weeks old Balb/c mice (Iffa Credo) were used in each group. 14 days post II, the spleen and lymph nodes were taken for immunological read out and blood sampling for serology.

• **Immunological read out:**

Proliferation assay:

For *in vitro* assay, lymphocytes were prepared by crushing the spleen or the popliteal lymph nodes from the vaccinated mice at day 28

An aliquot of 2 X 10⁵ cells was plated in triplicate in 96 well plates with decreasing concentrations (10, 1, 0.1, 0.01 µg/ml) of protD 1/3 18 E7 His to restimulate the cells *in vitro* (72 Hrs). T cell proliferation was measured by 3H thymidine incorporation. The results are expressed as stimulation index (cpm sample/ cpm baseline)

Figure 34 and 35 compares the ability of protD 1/3 18 E7 to stimulate the proliferation of splenocytes or lymph node cells primed *in vivo* either by ProtD1/3 18 E7 His or Prot D1/3 18 E7 His + adjuvant and shows that only a basal lymphoproliferation is seen in mice that received the protein alone, on the contrary, high proliferative responses in spleen and very high responses in lymph nodes were detected in mice immunised with protD1/3 18 E7 His in adjuvant.

Cytokine production

- The cytokines (IL-5 and IFNγ) produced in the culture supernatant after a 96 Hrs period of *in vitro* re-stimulation of spleen or lymph node cells, with medium or with the ProtD1/3 18E7 (1 or 3 µg/ml) was measured by ELISA as described:

• IFNγ (Genzyme)

Quantitation of IFNγ was performed by Elisa using reagents from Genzyme. Samples and antibody solutions were used at 50 µl per well. 96-well microtiter plates

(Maxisorb Immuno-plate, Nunc, Denmark) were coated overnight at 4°C with 50 µl of hamster anti-mouse IFNγ diluted at 1.5 µg/ml in carbonate buffer pH 9.5. Plates were then incubated for 1 hr at 37°C with 100 µl of PBS containing 1% bovine serum albumin and 0.1% Tween 20 (saturation buffer). Two-fold dilutions of supernatant from in vitro stimulation (starting at 1/2) in saturation buffer were added to the anti-IFNγ-coated plates and incubated for 1 hr 30 at 37°C. The plates were washed 4 times with PBS Tween 0.1% (wash buffer) and biotin-conjugated goat anti-mouse IFNγ diluted in saturation buffer at a final concentration of 0.5 µg/ml was added to each well and incubated for 1 hr at 37°C. After a washing step, AMDEX conjugate (Amersham) diluted 1/10000 in saturation buffer was added for 30 min at 37°C. Plates were washed as above and incubated with 50 µl of TMB (Biorad) for 15 min. The reaction was stopped with H₂SO₄ 0.4N and read at 450 nm. Concentrations were calculated using a standard curve (mouse IFNγ standard) by SoftmaxPro (four parameters equation) and expressed in pg/ml.

• IL5 (Pharmingen)

Quantitation of IL5 was performed by Elisa using reagents from Pharmingen. Samples and antibody solutions were used at 50 µl per well. 96-well microtiter plates (Maxisorb Immuno-plate, Nunc, Denmark) were coated overnight at 4°C with 50 µl of rat anti-mouse IL5 diluted at 1 µg/ml in carbonate buffer pH 9.5. Plates were then incubated for 1 hr at 37°C with 100 µl PBS containing 1% bovine serum albumin and 0.1% Tween 20 (saturation buffer). Two-fold dilutions of supernatant from in vitro stimulation (starting at 1/2) in saturation buffer were added to the anti-IFNγ-coated plates and incubated for 1 hr 30 at 37°C. The plates were washed 4 times with PBS Tween 0.1% (wash buffer) and biotin-conjugated rat anti-mouse IL5 diluted in saturation buffer at a final concentration of 1 µg/ml was added to each well and incubated for 1 hr at 37°C. After a washing step, AMDEX conjugate (Amersham) diluted 1/10000 in saturation buffer was added for 30 min at 37°C. Plates were washed as above and incubated with 50 µl of TMB (Biorad) for 15 min. The reaction was stopped with H₂SO₄ 0.4N and read at 450 nm. Concentrations were calculated using a standard curve (recombinant mouse IL5) by SoftmaxPro (four parameters equation) and expressed in pg/ml.

Starting with spleen cells, no IL-5 could be detected whatever the group tested, on the contrary, a very high production of IFN γ production was observed in all groups, with only a slight increase in the group of mice that received the SBAS1c adjuvanted protein compared to the other groups. This suggest the induction of a TH1 type of immune response.

Regarding lymph node cells, a very weak IFN γ production was obtained in the group of mice that received the protein alone and a 5-10 fold increase is observed with the adjuvanted protein. IL5 could only be detected in the group of mice receiving the SBAS2 adjuvanted protein.

Figure 36 and 37 compares the ability of ProtD1/3 18 E7 His to stimulate the production of cytokines (IFN γ and IL5) after in vitro re-stimulation of spleen or lymph node cells respectively.

Antibody response

Individual serum were taken at the same time as the organs and submitted to indirect ELISAs.

2.5 μ g/ml of purified of protD1/3 18E7 protein HPV18 was used as coated antigen. After saturation in PBS + 1% newborn calf serum 1 Hr at 37°C, the sera were serially diluted (starting at 1/100) in the saturation buffer and incubated O/N at 4°C or 90min at 37°C. After washing in PBS Tween 20 0.1%, biotinylated goat Anti mouse Ig (1/1000) or goat anti mouse Ig subclass (total IgG, IgG1, IgG2a, IgG2b) antisera (1/5000) were used as second antibodies, after an incubation of 90 min at 37°C, streptavidin coupled to peroxidase was added and TMB (tetra-methyl-benzidine / peroxide) was used as substrate, after 10 min. the reaction was stopped with H2SO4 0.5 M and the O.D.450 was determined.

A very weak antibody response is triggered with 2 injections of ProtD 1/3 18 E7 alone. The total IgG level was greatly increased by the addition of adjuvants to the protein vaccine.

The analysis of the concentrations of the different IgG subclass show that when the protein was injected in the presence of adjuvants, DQS21 3D-MPL or SB62, QS21/3D-MPL, a slight increase of the IgG2a subtype percentage was obtained: 28% IgG1, 48% IgG2a and 43% IgG1, 44% IgG2a respectively, compared to 46% of IgG1, 32% of IgG2a with the non adjuvanted protein. The strongest antibody

response is obtained with the protein formulated in DQ alum with a clear shift in the isotype concentration (80% IgG1, 8% IgG2a). As the IgG2a isotype in Balb/c mice is generally considered to be associated with the induction of a TH1 type of immune response, these results suggested that the DQS21, 3D-MPL and SB62 QS21/3D-MPL adjuvants tend to increase the TH1 type profile of the humoral response while SBAS5 induce a clear TH2 type of response.

Figure 38. The comparison of the midpoint dilution of the serum and relative percentage of the different isotypes elicited by the vaccinations in the different groups of mice are shown.

CONCLUSION:

We have demonstrated that the fused protein: 1/3 Prot D and early protein E7 of HPV 16 induced a potent systemic antitumour immunity and the fusion protein ProtD1/3 and E7 of HPV18 has also been showed to be immunogenic in mice. Vaccination with the prot D1/3 E7 HPV16 fusion protein protected the mice from a tumour challenge with E7 expressing tumour cells and eliminated small pre-established tumours expressing the E7 of HPV16 injected at a distant site from the vaccination site.

We have demonstrated that the ProtD1/3 E7 HPV16 protein in adjuvant is capable of enhancing helper T cell proliferation suggesting that the antitumour immune response induced by this vaccine is at least in part associated with a CD4+ T cell response.

We have also demonstrated that a better antibody response was triggered by the vaccination with the ProtD1/3 E7 in the presence of the 3D-MPL containing adjuvant. The predominant isotype found in the serum of C57BL/6 mice being IgG2b suggesting that a TH1 type immune response was raised.

CLAIMS

1. An E6 or E7 protein or E6/E7 fusion protein from HPV linked to an immunological fusion partner.
2. A protein as claimed in claim 1 wherein the fusion partner is selected from the group; protein D or a fragment thereof from Heamophilus influenzae B, lipoprotein D or fragment thereof from Heamophilus influenzae B, NS1 or fragment thereof from Influenzae Virus, and LYTA or fragment thereof from Streptococcus Pneumoniae.
3. A protein as claimed in claim 1 or 2 wherein the E6 or E7 proteins are derived from HPV16 or HPV18.
4. A protein as claimed in claim 1, 2 or 3 wherein the E7 protein is mutated.
5. A protein as claimed in claim 1, 2 or 3 wherein the E6 protein is mutated.
6. A protein as claimed in any of claims 1 to 5 additionally comprising a hisitidine tag of at least 4 hisitidine residues.
7. A fusion protein comprising a heterologous protein, a hisitidine tag and a C-LYTA tag.
8. A DNA sequence encoding a protein as claimed herein.
9. A vaccine containing a protein as claimed in any of claims 1 to 7 and a pharmaceutically acceptable diluent or excipient.
10. A vaccine as claimed in claim 9 additionally comprising an adjuvant.
11. A vaccine as claimed in claim 9 or 10 wherein the protein is presented in an oil in water emulsion vehicle.
12. A vaccine as claimed in claim 10 or 11 wherein the adjuvant comprises 3D-MPL or QS21 or both.
13. A vaccine as claimed herein comprising an additional HPV antigen.

14. A vaccine as claimed herein for use in medicine.
15. Use of a protein as claimed herein for the manufacture of a vaccine for immunotherapeutically treating a patient suffering from HPV induced tumour lesions (benign or malignant).
- 5 16. Use of a protein as claimed herein for the manufacture of a vaccine to prevent HPV viral infection.
17. A vector containing a DNA sequence of claim 8.
18. A vector containing a DNA sequence as claimed in claim 8 and a DNA sequence encoding thioredoxin.
- 10 19. A host transformed with a DNA sequence of claim 8.
20. A host transformed with a vector of claim 17 or 18.
21. A host as claimed in claim 19 additionally transformed with a DNA sequence encoding thioredoxin.
- 15 22. A process for the production of a protein as claimed herein comprising transforming a host cell with a DNA sequence of claim 6, expressing said sequence and isolating the desired product.
23. A process for the production of a vaccine as claimed herein, comprising admixing a protein as claimed herein with a suitable adjuvant, diluent or other pharmaceutically acceptable excipient.

Protein D1/3 E7 his

1 MDPSSSHSNM ANTQMKSDKI IIAHRGASGY LPEHTLESKA LAFAQQADYL
51 EQDLAMTKDG RLVVIHDHFL DGLTDVAKKF PHRHRKDGRY YVIDFTLKEI
5 101 QSLEMTENFE TMAMHGDTP T LHEYMLDLQP ETTDLICYEQ LNDSEEEDE
151 IDGPAGQAEP DRAHYNIVTF CCKCDSTLRL CVQSTHVDIR TLEDLLMGTL
10 201 GIVCPICSQK PTSGHHHHHH *

Figure 1 b

**Sequence of plasmid expressing fusion protein ProtDthr126-E7-His
tail (E7 from HPV16).**

15 1 ATGGATCCAA GCAGCCATTC ATCAAATATG GCGAATACCC AAATGAAATC
51 AGACAAAATC ATTATTGCTC ACCGTGGTGC TAGCGGTTAT
TTACCAGAGC
101 ATACGTTAGA ATCTAAAGCA CTTGCGTTTG CACAACAGGC
TGATTATTTA
20 151 GAGCAAGATT TAGCAATGAC TAAGGATGGT CGTTTAGTGG
TTATTCACGA
201 TCACTTTTTA GATGGCTTGA CTGATGTTGC GAAAAAATTC
CCACATCGTC
251 ATCGTAAAGA TGGCCGTTAC TATGTCATCG ACTTTACCTT
25 AAAAGAAATT
301 CAAAGTTTAG AAATGACAGA AAACTTTGAA ACCATGGCCA
TGCATGGAGA
351 TACACCTACA TTGCATGAAT ATATGTTAGA TTTGCAACCA
GAGACAACTG
30 401 ATCTCTACTG TTATGAGCAA TTAAATGACA GCTCAGAGGA
GGAGGATGAA
451 ATAGATGGTC CAGCTGGACA AGCAGAACCG GACAGAGCCC
ATTACAATAT
501 TGTAACCTTT TGTGCAAGT GTGACTCTAC GCTTCGGTTG TCGGTACAAA
35 551 GCACACACGT AGACATTCGT ACTTTGGAAG ACCTGTTAAT
GGGCACACTA
601 GGAATTGTGT GCCCATCTG TTCTCAGAAA CCAACTAGTG

GCCACCATCA

651 CCATCACCAT TAA

Figure 1

5

10

15


20

25

30

35

40

Construction of plasmid pRIT 14497 (TCA 307)**Figure 2**


SEQUENCE OF PROT.D1/3 E6 His / HPV 16.**Nucleotidic sequence**

ATGGATCCAAGCAGCCATTTCATCAAATATGGCGAATACCCAAATGAAATC 50
 5 AGACAAAATCATTATTGCTCACCGTGGTGCTAGCGGTTATTTACCAGAGC 100
 ATACGTTAGAACTCTAAAGCACTTGGCTTTGCACAACAGGCTGATTATTTA 150
 GAGCAAGATTTAGCAATGACTAAGGATGGTCGTTTAGTGGTTATTCACGA 200
 TCACCTTTTAGATGGCTTGACTGATGTTGCGAAAAAATCCCATCATCGTC 250
 ATCGTAAAGATGGCCGTTACTATGTCATCGACTTTACCTTAAAAGAAATT 300
 10 CAAAGTTTAGAAATGACAGAAAACTTGAACCATGGCCATGTTTCAGGA 350
 CCCACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAA 400
 CAACTATACATGATATAATATTAGAATGTGTGTACTGCAAGCAACAGTTA 450
 CTGCGACGTGAGGTATATGACTTTGCTTTTCGGGATTTATGCATAGTATA 500
 TAGAGATGGGAATCCATATGCTGTATGTGATAAATGTTTAAAGTTTATT 550
 15 CTAATAATTAGTGAGTATAGACATTATTGTTATAGTTTGTATGGAACAACA 600
 TTAGAACAGCAATACAACAAACCGTTGTGTGATTTGTTAATTAGGTGTAT 650
 TAACTGTCAAAAGCCACTGTGTCTGAAGAAAAGCAAAGACATCTGGACA 700
 AAAAGCAAAGATTCCATAATATAAGGGGTCGGTGGACCGGTGATGTATG 750
 TCTTGTTCGAGATCATCAAGAACACGTAGAGAAACCCAGCTGACTAGTGG 800
 20 CCACCATCACCATCACCATTAA 822

Peptidic sequence

MDPSSSHSNMANTQMKSDKIIIAHRGASGYLPEHTLESKALAFQAQADYL 50
 EQDLAMTKDGRVLVIHDFLDGLTDVAKKFPHRHRKDGRYYVIDFTLKEI 100
 QSLEMTENFETMAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQL 150
 25 LRREVVYDFAFRDLCIVYRDGNPYAVCDKCLKFYISKISEYRHYCYSLYGT 200
 LEQQYNKPLCDLLIRCINCQKPLCPEEKQRHLDDKKQRFHNIRGRWTGRCM 250
 SCCRSSRTRRETQLTSGHHHHHHH. 274

Figure 3

Construction of plasmid pRIT 14556 (TCA 309)

Constitution of a fusion protein between E6 and E7: deletion of 5 nucleotides by insertion of syn adaptor between Afl III and Nsi I





Figure 4

Construction of plasmid pRIT 14512 (TCA 311)**Figure 5**

SEQUENCE OF PROT.D1/3 - E6 - E7 - His / HPV 16


Peptidic sequence

ATGGATCCAAGCAGCCATTTCATCAAAATATGGCGAATACCCAAATGAAATC 50
 AGACAAAATCATTATTGCTCACCGTGGTGCTAGCGTTATTTACCAGAGC 100
 5 ATACGTTAGAACTCTAAAGCACTTGCCTTTGCACAACAGGCTGATTATTTA 150
 GAGCAAGATTTAGCAATGACTAAGGATGGTCGTTTAGTGGTTATTCACGA 200
 TCACTTTTATAGATGGCTTGACTGATGTTGCGAAAAAATCCACATCGTC 250
 ATCGTAAAGATGGCCGTTACTATGTCATCGACTTTACCTTAAAAAGAAAT 300
 CAAAGTTTAGAAATGACAGAAAACTTTGAAACCATGGCCATGTTTCAGGA 350
 10 CCCACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAA 400
 CAACTATACATGATATAATATTAGAAATGTGTACTGCAAGCAACAGTTA 450
 CTGCGACGTGAGGTATATGACTTTTGCTTTTCGGGATTTATGCATAGTATA 500
 TAGAGATGGGAATCCATATGCTGTATGTGATAAATGTTTAAAGTTTTATT 550
 CTAAAATTAGTGAGTATAGACATTATTGTTATAGTTGTATGGAACAACA 600
 15 TTAGAACAGCAATACAACAAACCGTTGTGTGATTGTTAATTAGGTGTAT 650
 TAACTGTCAAAAGCCACTGTGTCCTGAAGAAAAGCAAAGACATCTGGACA 700
 AAAAGCAAAGATTCCATAATATAAGGGTTCGGTGGACCGGTGATGTATG 750
 TCTTGTTGCAGATCATCAAGAACACGTAGAGAAACCCAGCTGATGCATGG 800
 AGATACACCTACATTGCATGAATATATGTTAGATTGCAACCAGAGACAA 850
 20 CTGATCTCTACTGTTATGAGCAATTAATGACAGCTCAGAGGAGGAGGAT 900
 GAAATAGATGGTCCAGCTGGACAAGCAGAACCGGACAGAGCCATTACAA 950
 TATTGTAACCTTTTGTGCAAGTGTGACTCTACGCTTCGGTTGTGCGTAC 1000
 AAAGCACACAGCTAGACATTCTGACTTTTGAAGACCTGTTAATGGGCACA 1050
 CTAGGAATTGTGTGCCCATCTGTTCTCAGAAACCAACTAGTGGCCACCA 1100
 25 TCACCATCACCATTAA 1116

Peptidic sequence

MDPSSSSNMANTQMKSJKIIAHRGASGYLPEHTLESKALAFQAQADYL 50
 EQDLAMTKDGRLLVIIHDHFLDGLTDVAKFPHRHRKDGRIYVIDFTLKEI 100
 30 QSLEMTENFETMAMFQDPQERPRKLPLQCTELQTTIHDIIILECVYCKQQL 150
 LRREVYDFAFRDLICIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTT 200
 LEQQYNKPLCDLLIRCINCQKPLCPEEKQRHLDDKQRFHNRGRWTRGRM 250
 SCCRSRTRRETQLMHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEED 300
 EIDGPAGQAEPRAHYNIVTFCKCDSTLRLCVQSTHVDIRLTLEDLLMGT 350
 35 LGIVCPICISQKPTSGHHHHHH. 372

Figure 6

Construction of plasmid pRIT 14733**Figure 7**

SEQUENCE OF PROT.D1/3 - E7 mutated (cys24 → gly, glu26 → gln) HPV16.

5 Nucleotidic sequence:

ATGGATCCAAGCAGCCATTTCATCAAATATGGCGAATACCCAAATGAAATC 50
 AGACAAAATCATTATTGCTCACCGTGGTGCTAGCGGTTATTTACCAGAGC 100
 ATACGTTAGAATCTAAAGCAGCTTGCCTTTGCACAACAGGCTGATTATTTA 150
 10 GAGCAAGATTAGCAATGACTAAGGATGGTCGTTTAGTGTTATTCACGA 200
 TCACITTTTAGATGGCTTGACTGATGTTGCGAAAAAATCCCAACATCGTC 250
 ATCGTAAAGATGGCCGTTACTATGTCAATCGACTTTACCTTAAAGAAATT 300
 CAAAGTTTAGAAATGACAGAAACTTTGAAACCATGGCCATGCATGGAGA 350
 TACACCTACATTGCATGAATATATGTTAGATTGCAACAGAGACAACCTG 400
 15 ATCTCTACGGTTATCAGCAATTAATGACAGCTCAGAGGAGGAGGATGAA 450
 ATAGATGGTCCAGCTGGACAAGCAGAACCGGACAGAGCCATTACAATAT 500
 TGTAACCTTTTGTGCAAGGTGACTCTACGCTTCGGTTGTGCGTACAAA 550
 GCACACACGTAGACATTCGTACTTTGGAAGACCTGTTAATGGGCACACTA 600
 GGAATTGTGTGCCCCATCTGTTCTCAGAAACCAACTAGTGGCCACCATCA 650
 20 CCATCACCATTAA 663

Mutations: T409 → G

G415 → C

Peptidic sequence:

MDPSSHSSNMANTQMKSDKIIIAHRGASGYLPEHTLESKALAFQAQADYL 50
 25 EQDLAMTKDGRLLVVIHDHFLDGLTDVAKKFPHRHRKDGRYYVIDFTLKEI 100
 QSLEMTENFETMAMHGDPTLHEYMLDLQPETTDLYGYQLNDSSEEEDE 150
 IDGPAGQAEPRAHYNIVTFCKCDSLRLCVQSTHVDIRLTLEDLLMGTL 200
 GIVCPICSQKPTSGHHHHHH. 221


mutated amino acids: cys24 → gly (=C24→G), glu26 → gln (=E26→Q) of E7 are
 30 residues 137 and 139 of the fusion protein.

N term M D P -ProtD1/3(aa4 → 111)-M A-mutated E7(aa 114 → 211)-

TSGHHHHHH Cterm.

Figure 8

35

Construction of plasmid pRIT 14634 (TCA332)

5

Figure 9

10

SEQUENCE OF CLYTA - E6 - His**Nucleotidic sequence**


5 ATGAAAGGGGGAATTGTACATTCAGACGGCTCTTATCCAAAAGACAAGTT 50
 TGAGAAAATCAATGGCACTTGGTACTACTTTGACAGTTCAGGCTATATGC 100
 TTGCAGACCGCTGGAGGAAGCACACAGACGGCAACTGGTACTGGTTCGAC 150
 AACTCAGGCGAAATGGCTACAGGCTGGAAGAAAATCGCTGATAAGTGTA 200
 CTATTTCAACGAAGAAGGTGCCATGAAGACAGGCTGGGTCAAGTACAAG 250
 10 ACACCTTGGTACTACTTAGACGCTAAAGAAGGCGCCATGGTATCAAATGCC 300
 TTTATCCAGTCAGCGGACGGAACAGGCTGGTACTACCTCAAACAGACGG 350
 AACACTGGCAGACAGGCCAGAATTGGCCAGCATGCTGGACATGGCCATGT 400
 TTCAGGACCCACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAG 450
 CTGCAACAACACTATACATGATATAATATTAGAATGTGTGTACTGCAAGCA 500
 15 ACAGTTACTGCGACGTGAGGTATATGACTTTGCTTTTCGGGATTTATGCA 550
 TAGTATATAGAGATGGGAATCCATATGCTGTATGTGATAAATGTTAAAG 600
 TTTTATTCTAAAATTAGTGAGTATAGACATTATTGTTATAGTTTGTATGG 650
 AACACATTAGAACAGCAATACAACAAACCGTTGTGTGATTTGTTAATTA 700
 GGTGTATTAAGTGCAAAAGCCACTGTGTCCTGAAGAAAAGCAAAGACAT 750
 20 CTGGACAAAAAGCAAAGATTCCATAATATAAGGGGTCGGTGGACCGGTCG 800
 ATGTATGTCTTGTTCAGATCATCAAGAACACGTAGAGAAACCCAGCTGA 850
 CTAGTGGCCACCATCACCATCACCATTAA 879

Peptidic sequence

25 MKGGIVHSDGSYPKDKFEKINGTWYFYDSSGYMLADRWKHTDGNWYWFD 50
 NSGEMATGWKKIADKWYFNEEGAMKTGWVKYKDTWYYLDAKEGAMVSNA 100
 FIQSADGTGWYYLKPDGTLADRPELASMLDMAMFQDPQERPRKLPQLCTE 150
 LQTHIHDIILECVYCKQQLRREVYDFAFRDLICIVYRDGNPYAVCDKCLK 200
 FYSKISEYRHYCYSLYGTLEQQYNKPLCDLLIRCINCQKPLCPPEEKQRH 250
 30 LDKKQRFHNIRGRWTGRCMSCRSSRTRRETQLTSGHHHHHHH. 293

Figure 10

35

Construction of plasmid pRiT 14626 (TCA330)**Figure 11**


SEQUENCE OF CLYTA - E7 - His.**Nucleotidic sequence**

ATGAAAGGGGGAATTGTACATTACAGACGGCTCTTATCCAAAAGACAAGTT 50
 5 TGAGAAAAATCAATGGCACTTGGTACTACTTTGACAGTTACAGGCTATATGC 100
 TTGCAGACCGCTGGAGGAAGCACACAGACGGCAACTGGTACTGGTTCGAC 150
 AACTCAGGCGAAATGGCTACAGGCTGGAAGAAAAATCGTGATAAGTGGTA 200
 CTATTCAACGAAGAAGGTGCCATGAAGACAGGCTGGGTCAAGTACAAG 250
 ACACITGGTACTACTTAGACGCTAAAGAAGGCGCCATGGTATCAAATGCC 300
 10 TTTATCCAGTCAGCGGACGGAACAGGCTGGTACTACCTCAAACAGACGCG 350
 AACACTGGCAGACAGGCCAGAATTGGCCAGCATGCTGGACATGGCCATGC 400
 ATGGAGATACACCTACATTGCATGAATATATGTTAGATTGCAACCAGAG 450
 ACAACTGATCTCTACTGTTATGAGCAATTAATGACAGCTCAGAGGAGGA 500
 GGATGAAATAGATGGTCCAGCTGGACAAGCAGAACCGGACAGAGCCCAT 550
 15 ACAATATTGTAACCTTTTGTGCAAGTGTGACTCTACGCTTCGGTTGTGC 600
 GTACAAAGCACACACGTAGACATTCGTACTTTGGAAGACCTGTTAATGGG 650
 CACACTAGGAATTGTGTGCCCCATCTGTTCTCAGAAACCAACTAGTGGCC 700
 ACCATCACCATCACCATTAA 720

Peptidic sequence

20 MKGGIVHSDGSYPKDKFEKINGTWYYFDSSGYMLADRWKHTDGNWYWF 50
 NSGEMATGWKKIADKWYYFNEEGAMKTGWVKYKDTWYYLDAKEGAMVSNA 100
 FIQSADGTGWYYLKP DGT LADRP ELASMLDMAMHGDPTLHEYMLDLQPE 150
 TTDLYCYEQLNDSSEEDEIDGPAQAE PDRAHYNIVTFCKCDSTLR L C 200
 VQSTHVDIRLTEDLLMGT LGIVCPIC SQKPTSGHHHHHH. 240

Figure 12

Construction of plasmid pRIT 14634 (TCA331)

5

Figure 13

10

SEQUENCE OF CLYTA - E6E7 - His.**Nucleotidic sequence**

ATGAAAGGGGGAATTGTACATTCAGACGGCTCTTATCCAAAAGACAAGTT 50
5 TGAGAAAAATCAATGGCACTTGGTACTACTTTGACAGTTCAGGCTATATGC 100
TTGCAGACCGCTGGAGGAAGCACACAGACGGCAACTGGTACTGGTTCGAC 150
AACTCAGGCGAAATGGCTACAGGCTGGAAGAAAATCGCTGATAAGTGGTA 200
CTATTTCAACGAAGAAGGTGCCATGAAGACAGGCTGGGTCAAGTACAAG 250
ACACTTGGTACTACTTAGACGCTAAAGAAGGCCCATGGTATCAAATGCC 300
10 TTTATCCAGTCAGCGGACGGAACAGGCTGGTACTACCTCAAACGACAGCG 350
AACACTGGCAGACAGGCCAGAATTGGCCAGCATGCTGGACATGGCCATGT 400
TTCAGGACCCACAGGAGCGACCCAGAAAAGTTACCACAGTTATGCACAGAG 450
CTGCAAACAACTATACATGATATAATATTAGAATGTGTGACTGCAAGCA 500
ACAGTTACTGCGACGTGAGGTATATGACTTTTGCTTTTCGGGATTTATGCA 550
15 TAGTATATAGAGATGGGAATCCATATGCTGTATGTGATAAATGTTAAAG 600
TTTTATTCTAAAATTAGTGAGTATAGACATTATTGTTATAGTTGTATGG 650
AACAACATTAGAACAGCAATACAACAAACCGTTGTGTGATTGTTAATTA 700
GGTGATTAACTGTCAAAGCCACTGTGCTCTGAAGAAAAGCAAAGACAT 750
CTGGACAAAAGCAAAGATTCCATAATATAAGGGGTCCGTGGACCGGTG 800
20 ATGTATGTCTTGTTCAGATCATCAAGAACACGTAGAGAAACCCAGCTGA 850
TGCATGGAGATACACCTACATTGCATGAATATATGTTAGATTGCAACCA 900
GAGACAACCTGATCTCTACTGTTATGAGCAATTAATGACAGCTCAGAGGA 950
GGAGGATGAAATAGATGGTCCAGCTGGACAAGCAGAACCGGACAGAGCCC 1000
ATTACAATATTGTAACCTTTTGTGTGCAAGTGTGACTCTACGCTTCGGTTG 1050
25 TGCGTACAAAGCACACAGTAGACATTTCGTACTTTGGAAGACCTGTTAAT 1100
GGGCACACTAGGAATTGTGTGCCCATCTGTTCTCAGAAACCAACTAGTG 1150
GCCACCATCACCATCACCATTAA 1173

Peptidic sequence

MKGGIVHSDGSYPKDKFEKINGTWYFFDSSGYMLADRWRKHTDGNWYWF 50
30 NSGEMATGWKKIADKWYFFNEEGAMKTGWVKYKDTWYLDAKEGAMVSN 100
FIQSADGTGWYYLKPDTLADRP ELASMLDMAMFQDPQERPRKLPQLCTE 150
LQTTIHILECVYCKQQLRREVYDFRDLICIVYRDGNPYAVCDKCLK 200
FYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLCPEEKQRH 250

LDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQLMHGDTPTLHEYMLDLQP 300
ETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNIVTFCKCDSTLRL 350
CVQSTHVDIRTLEDLLMGTLGIVCPICSQKPTSGHHHHHH. 391

Figure 14

5

10

15

20


25

30

35

40

45

Construction of pLASMID pRIT 14532 (TCA 316).**Figure 15**

5

10

SEQUENCE OF PROT.D1/3 -E7-HIS /HPV18**Nucleotide Sequence**

5 ATGGATCCAAGCAGCCATTCAAAATATGGCGAATACCCAAATGAAATC 50
AGACAAAATCATTATTGCTCACCGTGGTGCTAGCGGTTATTTACCAGAGC 100
ATACGTTAGAATCTAAAGCACTTGC GTTGCACAACAGGCTGATTATTTA 150
GAGCAAGATTAGCAATGACTAAGGATGGTCGTTTAGTGTTATTACGA 200
10 TCACTTTTATAGATGGCTTGACTGATGTTGCGAAAAAATCCCACATCGTC 250
ATCGTAAAGATGGCCGTTACTATGTCATCGACTTTACCTTAAAGAAATT 300
CAAAGTTTAGAAATGACAGAAAACCTTGA AACCATGGCCATGCATGGACC 350
TAAGGCAACATTGCAAGACATTGTATTGCATTTAGAGCCCCAAAATGAAA 400
TTCCGGTTGACCTTCTATGTCACGAGCAATTAAGCGACTCAGAGGAAGAA 450
15 AACGATGAAATAGATGAAGTTAATCATCAACATTTACCAGCCCGACGAGC 500
CGAACCAACAACGTCACACAATGTTGTGTATGTGTTGTAAGTGTGAAGCCA 550
GAATTGAGCTAGTAGTAGAAAGCTCAGCAGACGACCTTCGAGCATTCCAG 600
CAGCTGTTTCTGAACACCTGTCTTTGTGTGTCGGTGGTGCATCCCA 650
GCAGACTAGTGGCCACCATCACCATCACCATTAA 684

Peptidic Sequence

MDPSSHSSNMANTQMKSDKIIIAHRGASGYLPEHTLESKA 40
LAFAQQADYLEQDLAMTKDGRLLVVIHDHFLDGLTDVAKKF 80
PHRHRKDG RYYVIDFTLKEIQSLEM TENFETMAMHGPKAT 120
LQDIVLHLEPQNEIPVDLLCHEQLSDSEEENDEIDEVNHQ 160
25 HLPARRAEPQRHTMLCMCKCEARIELVVESSADDLRAFQ 200
QLFLNLSFVCPWCASQQTSGHHHHHH. 228

Figure16

30

35


Construction of plasmid pRIT 14523 (TCA313)

Figure 17

SEQUENCE OF THIOREDOXIN

5

MSDKIIHLTDDSFDTDLKADGAILVDFWAEWCGPCKMIA 40
PILDEIADEYQGKLTVAKLNIDQNPGTAPKYGIRGIPTLL 80
LFKNGEVAATKVGALSKGQLKEFLDANLA. 110

10

Figure 18


15

20

25

30

35

Construction of plasmid pRIT 14831**Figure 19**

SEQUENCE OF PROT.D1/3 - E7 mutated (cys27 → gly, glu29 → gln) HPV18.**Nucleotide sequence:**

ATGGATCCAAGCAGCCATTTCATCAAAATATGGCGAATACCCAAATGAAATC 50
 5 AGACAAAATCATTATTGCTCACCGTGGTGCTAGCGGTTATTTACCAGAGC 100
 ATACGTTAGAATCTAAAGCACTTGGCTTTGCACAACAGGCTGATTATTTA 150
 GAGCAAGATTTAGCAATGACTAAGGATGGTCGTTTAGTGGTTATTCACGA 200
 TCACCTTTTATGATGGCTTGACTGATGTTCGAAAAAATCCCATCATCGTC 250
 ATCGTAAAGATGGCCGTACTATGTCATCGACTTTACCTAAAAAATAATT 300
 10 CAAAGTTTAGAAATGACAGAAAACCTTGAAACCATGGCCATGCATGGACC 350
 TAAGGCAACATTGCAAGACATTGTATTGCAATTAGAGCCCCAAAAATGAAA 400
 TTCCGGTTGACCTTCTAGGTCACCAAGCAATTAAGCGACTCAGAGGAAGAA 450
 AACGATGAAATAGATGGAGTTAATCATCAACATTTACCAGCCGACGAGC 500
 CGAACCACAACGTCACACAATGTTGTGTATGTGTGTAAGTGTGAAGCCA 550
 15 GAATTGAGCTAGTAGTAAAGCTCAGCAGACGACCTTCGAGCATTCCAG 600
 CAGCTGTTTCTGAACACCCTGTCTTTGTGTGTCGCGGTGTGCATCCCA 650
 GCAGACTAGTGGCCACCATCACCATCACCATTAA 684


Mutations: T418 → G

G424 → C

20 Peptidic sequence:

MDPSSHSSNMANTQMKSCKIIIAHRGASGYLPEHTLESKALAFQAQADYL 50
 EQDLAMTKDGRLLVVIHDFLDGLTDVAKKFPHRHRKDGRYYVIDFTLKEI 100
 QSLEMTENFETMAMHGPKATLQDIVLHLEPQNEIPVDLLGHQQLSDSEEE 150
 NDEIDGVNHQHLPARRAEPQRHTMLCMCKCEARIELVVESSADDLRAFQ 200
 25 QLFLNLSFVCPWCASQQTSGHHHHH. 228
 mutated amino acids: cys27 → gly (=C27→G), glu29 → gln (=E29→Q) of E7 are residues
 140 and 142 of the fusion protein.
 N term M D P -**ProtD1/3**(aa4 → 111)-M A-**mutated E7**(aa 114 → 218)-TSGHHHHHHH
 Cterm.

Figure 20

Construction of plasmid pRIT 14526 (TCA 314)

5

Figure 21

10



SEQUENCE OF PROT.D1/3 - E6 - His / HPV18.**5 Nucleotide sequence**


ATGGATCCAAGCAGCCATTCATAAATATGGCGAATACCCAAATGAAATC 50
 AGACAAAATCATTATTGCTCACCGTGGTGCTAGCGGTATTTACCAGAGC 100
 ATACGTTAGAATCTAAAGCACTTGGCITTGCACAACAGGCTGATTATTTA 150
 10 GAGCAAGATTAGCAATGACTAAGGATGGTCGTTTGTGTTATTCACGA 200
 TCACTTTTATAGATGGCTTGACTGATGTTGCGAAAAAATTCACATCGTC 250
 ATCGTAAAGATGGCCGTACTATGTATCGACTTTACCTTAAAGAAATT 300
 CAAAGTTTAGAAATGACAGAAAACTTTGAAACCATGGCGCGCTTTGAGGA 350
 TCCAACACGGCGACCCTACAAGCTACCTGATCTGTGCACGGAAGTGAACA 400
 15 CTTCACTGCAAGACATAGAAAATAACCTGTGTATATTGCAAGACAGTATTG 450
 GAACTTACAGAGGTATTTGAATTTGCATTTAAAGATTTATTTGTGGTGTA 500
 TAGAGACAGTATACCGCATGCTGCATGCCATAAATGTATAGATTTTATT 550
 CTAGAATTAGAGAATTAAGACATTATTCAGACTCTGTGTATGGAGACACA 600
 TTGGAAAACTAATAACACTGGGTATACAATTTATTAATAAGGTGCCT 650
 20 GCGGTGCCAGAAACCGTTGAATCCAGCAGAAAACTTAGACACCTTAATG 700
 AAAACGACGATTTACAACATAGCTGGGCACTATAGAGGCCAGTGCCAT 750
 TCGTGCTGCAACCGAGCAGACAGGAACGACTCCAACGACGCAGAGAAAC 800
 ACAAGTAAGTAGTGGCCACCATCACCATCACCATTAA 837

Peptidic sequence

25 MDPSSSHSNMANTQMKSDKIIIAHRGASGYLPEHTLESKALAFQAQADYL 50
 EQDLAMTKDGRLLVVIHDHFLDGLTDVAKKFPHRHRKDRYVYIDFTLKEI 100
 QSLEMTENFETMARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVL 150
 ELTEVFEFKDLFVVYRDSIPAACHKCIDFYSRIREL RHYSDSVYGD 200
 LEKLTNTGLYNLLIRCLRCQKPLNPAEKLRLHNEKRRFHNIA GHYRGQCH 250
 30 SCCNRARQERLQRRRETQVTSGHHHHHH. 279

Figure 22

Construction of plasmid pRIT 14618 (TCA 320)**Figure 23**

Construction of plasmid pRIT 14567 (TCA328)

5

Figure 24

10

SEQUENCE OF PROT.D1/3 - E6 - E7 - His / HPV18.**Nucleotidic sequence**

5 ATGGATCCAAGCAGCCATTTCATCAAAATATGGCGAATACCCAAATGAAATC 50
 AGACAAAATCATTATTGCTCACCGTGGTGCTAGCGGTTATTACCAGAGC 100
 ATACGTTAGAATCTAAAGCACTTGCCTTTGCACAACAGGCTGATTATTTA 150
 GAGCAAGATTTAGCAATGACTAAGGATGGTCGTTTAGTGGTTATTCACGA 200
 TCACCTTTTAGATGGCTTGACTGATGTTGCGAAAAAATCCACATCGTC 250
 10 ATCGTAAAGATGGCCGTTACTATGTATCGACTTTACCTTAAAGAAATT 300
 CAAAGTTTAGAAATGACAGAAAACTTTGAAACCATGGCGCGCTTTGAGGA 350
 TCCAACACGGCGACCCCTACAAGCTACCTGATCTGTGCACGGAAGTGAACA 400
 CTTCACTGCAAGACATAGAAAACCTGTGTATATTGCAAGACAGTATTG 450
 GAACCTACAGAGGTATTGAATTTGCATTTAAAGATTTATTGTGGTGTA 500
 15 TAGAGACAGTATACCGCATGCTGCATGCCATAAATGTATAGATTTTATT 550
 CTAGAATTAGAGAAATTAAGACATTATTCAGACTCTGTGTATGGAGACACA 600
 TTGGAAAACTAATAACACTGGGTATACAATTTATTAATAAGGTGCCT 650
 GCGGTGCCAGAAACCGTTGAATCCAGCAGAAAACTTAGACACCTTAATG 700
 AAAAAACGACGATTCACAACATAGCTGGGCACTATAGAGGCCAGTGCCAT 750
 20 TCGTGCTGCAACCGAGCACGACAGGAACGACTCCAACGACGCAGAGAAAC 800
 ACAAGTAATGCATGGACCTAAGGCAACATTGCAAGACATTGTATTGCATT 850
 TAGAGCCCCAAAATGAAATCCGGTTGACCTTCTATGTCACGAGCAATTA 900
 AGCGACTCAGAGGAAGAAAACGATGAAATAGATGGAGTTAATCATCAACA 950
 TTTACCAGCCCGACGAGCCGAACCACAACGTCACACAATGTTGTGTATGT 1000
 25 GTTGTAAAGTGTGAAGCCAGAATTGAGCTAGTAGTAGAAAGCTCAGCAGAC 1050
 GACCTTCGAGCATTCCAGCAGCTGTTCTGAACACCCTGTCTTTGTGTG 1100
 TCCGTGGTGTGCATCCAGCAGACTAGTGGCCACCATCACCATCACCATT 1150
 AA 1152

Peptidic sequence

30 MDPSSSHSNMANTQMKSCKIIIAHRGASGYLPEHTLESKALAFQAQADYL 50
 EQDLAMTKDGRLLVVIHDFLDGLTDVAKKFPHRHRKDGRYYVIDFTLKEI 100
 QSLEMTENFETMARFEDPTRRYPKLPDLCTELNTSLQDIEITCVYCKTVL 150
 ELTEVFEFAFKDLFVVYRDSIPHAACHKCIDFYSRIRELRHYSDSVYGGDT 200
 LEKLTNTGLYNLLIRLCRCQKPLNPAEKLRLHLEKRRFHNIAHGHRGQCH 250

35

SCCNRARQERLQRRRETQVMHGPKATLQDIVLHLEPQNEIPVDLLCHEQL 300
SDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCKCEARIELVVESSAD 350
DLRAFQQLFLNTLSFVCPWCASQQTSGHHHHHH. 384

5

Figure 25

10

15

20

25

30

35


40

45

Figure n° 26

Therapeutic effect of vaccination with ProtD1/3 E7 of HPV16 formulations, on
TC1 tumor growth

10



15

20

25

Figure n° 27

**Lymphoproliferation on spleen cells
(stimulation index)**

72 Hrs *in vitro* restimulation with ProtD1/3E7 (0.1; 1 µg/ml)
(exp 96533)

Group 1: ProtD 1/3 E7

Group 2: ProtD 1/3 E7 + SB 62 Qs21 & 3 D MPL

Group 3: SB 62 Qs21 & 3 D MPL

Group 4: PBS




Figure N° 28

Lymphoproliferation on lymph node cells
(stimulation index)

72 Hrs *in vitro* restimulation with ProtD1/3E7 (1 µg/ml)
(exp 96533)

Group 1: ProtD 1/3 E7

Group 2: ProtD 1/3 E7 + SB 62 Qs21 & 3 D MPL

Group 3: SB 62 Qs21 & 3 D MPL

Group 4: PBS





Figure n° 29

Subclass-specific antibody response (exp 96533)

- 5 group 1: ProtD1/3 E7 HPV16
group 2: ProtD1/3 E7 HPV16+ SB 62 Qs21 & 3 D MPL
group 3: SB 62 Qs21 & 3 D MPL
group 4: PBS

10



15

20

25

30

Figure n° 30

Protective effect of vaccination with ProtD1/3 E7 HPV16 formulations against a TC1 tumor challenge (2 10e5 cells) (exp 96532)




Figure n° 31

Lymphoproliferation on spleen cells (Stimulation index) (Exp. 96532)

72 Hrs *in vitro* re-stimulation withA) ProtD1/3 E7 (1; 0.1 $\mu\text{g/ml}$)B) ProtD1/3 E7 (0.1; 0.01 $\mu\text{g/ml}$) coated on latex μbeads

Group 1: ProtD1/3 E7 HPV16

Group 2: ProtD1/3 E7 HPV16 + SB 62 Qs21 & 3 D MPL

Group 3: SB 62 Qs21 & 3 D MPL

Group 4: PBS





Figure n° 32

- 5 **Lymphoproliferation on lymph node cells**
 (Stimulation index) (Exp. 96532)
 72 Hrs *in vitro* re-stimulation with

- A) ProtD1/3 E7 (0.01 µg/ml)
 10 B) ProtD1/3 E7 (0.01 µg/ml) coated on latex µbeads


Group 1: ProtD1/3 E7 HPV16

Group 2: ProtD1/3 E7 HPV16 + SB 62 Qs21 & 3 D MPL

Group 3: SB 62 Qs21 & 3 D MPL

- 15 Group 4: PBS

A



B




Figure n° 33

Subclass-specific antibody response (exp 96532)

group 1: ProtD/3 E7 HPV16

group 2: ProtD1/3 E7 HPV16 + SB 62 Qs21 & 3 D MPL

group 3: SB 62 Qs21 & 3 D MPL

group 4: medium







Figure n° 34**Lymphoproliferation on spleen cells (stimulation index)**

72HRs in vitro re-stimulation with PD1/3 18E7 (10, 1, 0.1, 0.01 µg/ml)


(Exp 98038)

5

Group 1: ProtD 1/3 18 E7**Group 2:** ProtD 1/3 18 E7 + DQS21 + 3D-MPL**Group 3:** ProtD 1/3 18 E7 + QS21 + 3D-MPL + SB62 O/W**Group 4:** ProtD 1/3 18 E7 + DQS21 alum

10

spleen Gr	1	2	3	4
18E7 10µg	6	27	23	20
18E7 1µg	5	23	25	23
18E7 0.1µg	5	21	21	23
18 E70.01µg	4	14	15	18
baseline/cpm	1168	1359	1025	1268



15

Figure n° 35**Lymphoproliferation on popliteal Lymph nodes**

72HRs in vitro re-stimulation with PD1/3 18E7 (10, 1, 0.1, 0.01 µg/ml)

(Exp 98038)

Group 1: ProtD 1/3 18 E7**Group 2:** ProtD 1/3 18 E7 + DQS21 + 3D-MPL**Group 3:** ProtD 1/3 18 E7 + QS21 + 3D-MPL + SB62 O/W**Group 4:** ProtD 1/3 18 E7 + DQS21 alum

LN Group	1	2	3	4
18 E7 10	33	117	108	203
18E7 1	8	110	108	208
18 E7 0.1	4	95	95	196
18 E70.01	2	75	81	141
baseline	325	161	131	607




Figure n° 36

Cytokine production in the culture supernatant of spleen cells after 96 Hrs in vitro re-stimulation (ProtD1/3 18E7 1, 3 μ g/ml)


Group 1: ProtD 1/3 18 E7

5 **Group 2:** ProtD 1/3 18 E7 + DQ 3D-MPL

Group 3: ProtD 1/3 18 E7 + QS21, 3D-MPL, SB62 O/W

Group 4: ProtD 1/3 18 E7 + DQ, 3D-MPL alum

IFN γ production



10

IL5 production




Figure n° 37

Cytokine production in the culture supernatant of Lymph ode cells after 96 Hrs in vitro re-stimulation with ProtD1/3 18E7


Group 1: ProtD 1/3 18 E7

5 **Group 2: ProtD 1/3 18 E7 + DQS21 3DMPL +**

Group 3: ProtD 1/3 18 E7 + SB62 QS21/3DMPL

Group 4: ProtD 1/3 18 E7 + DQ Alum

IFN γ production



IL5 production






Figure n° 38**Antibody response and Isotypic (exp 98038)**

- Group 1: ProtD 1/3 18 E7
- 5 Group 2: ProtD 1/3 18 E7 + DQS21 3DMPL
- Group 3: ProtD 1/3 18 E7 + SB62 QS21/3DMPL
- Group 4: ProtD 1/3 18 E7 + MPL DQ alum

Groups	mid. Dil IgGt tot	IgG1 %	IgG2a %	IgG2b %
1	1500	46	32	22
2	84172	28	48	23
3	80545	43	44	13
4	213685	82	8	10





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/62, C07K 14/025, 16/08	A3	(11) International Publication Number: WO 99/10375 (43) International Publication Date: 4 March 1999 (04.03.99)
(21) International Application Number: PCT/EP98/05285 (22) International Filing Date: 17 August 1998 (17.08.98) (30) Priority Data: 9717953.5 22 August 1997 (22.08.97) GB (71) Applicant (for all designated States except US): SMITHK-LINE BEECHAM BIOLOGICALS S.A. [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): BRUCK, Claudine [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). CABEZON SILVA, Teresa [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). DELISSE, Anne-Marie, Eva, Fernande [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). GERARD, Catherine, Marie, Ghislaine [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). LOMBARDO-BENCHEIKH, Angela [FR/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE).		(74) Agent: DALTON, Marcus, Jonathan, William; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 10 June 1999 (10.06.99)
(54) Title: VACCINE AGAINST HPV (57) Abstract The present invention provides Human Papilloma Virus (HPV) fusion proteins, linked to an immunological fusion partner that provides T helper epitopes to the HPV antigen. Vaccine formulations are provided that are useful in the treatment or Prophylaxis of HPV induced lesions.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

Inter. Appl. No.
PCT/EP 98/05285

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/62 C07K14/025 C07K16/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 456 197 A (BEHRINGWERKE AG) 13 November 1991 see abstract see page 2, line 1-23 see page 2, line 25 - page 3, line 4 see claims ---	1,3-5, 8-11, 13-17, 19,20, 22,23
X	WO 96 26277 A (CANTAB PHARMA RES ;WHITTLE NIGEL RICHARD (GB); CARMICHAEL JEREMY P) 29 August 1996 see abstract see page 4, line 5 - page 15, line 34 see examples --- -/-	1,3-5, 8-11, 13-17, 19,20, 22,23

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "S" document member of the same patent family

Date of the actual completion of the international search

8 April 1999

Date of mailing of the international search report

16/04/1999

Name and mailing address of the ISA
European Patent Office, P.B. 5618 Patentlaan 2
NL - 2200 HV Rijswijk
Tel. (+31-70) 340-3340, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Panzica, G

INTERNATIONAL SEARCH REPORT

Inter. Appl. Application No
PCT/EP 98/05285

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 05248 A (SQUIBB BRISTOL MYERS CO) 2 April 1992 see abstract see page 7, line 5 - page 9, line 21 see examples ----	1,3-5, 8-11, 13-17, 19,20, 22,23
X	DE 44 41 197 C (DEUTSCHES KREBSFORSCH) 28 March 1996 see the whole document ----	1,3-5, 8-11, 13-17, 19,20, 22,23
X	WO 93 22338 A (UNIV LEIDEN) 11 November 1993 see the whole document ----	1,3-5, 8-11, 13-17, 19,20, 22,23
X	FR 2 586 428 A (PASTEUR INSTITUT) 27 February 1987 see abstract ----	1,3-5, 8-11, 13-17, 19,20, 22,23
A	EP 0 386 734 A (BEHRINGWERKE AG) 12 September 1990 see the whole document ----	1,3-5, 8-11, 13-17, 19,20, 22,23
A	WO 96 36702 A (SCHERING CORP) 21 November 1996 -----	7

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/ 05285

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark: although claim 7 shares no hierarchical dependence from any of the claims of the invention and although its formulations, relating to a heterologous protein fused to a c-LYTA tag and a histidine tag, is far beyond the scope of the present invention, a search has been carried out limitedly to the disclosures of the claims and examples, whereas the heterologous protein is an E6 or E7 from HPV-16 or HPV-18 (see Art.6 PCT and PCT Search Guidelines III.3.7).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 98/05285

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0456197	A	13-11-1991	DE 4015044 A AU 650648 B AU 7621291 A CA 2042236 A JP 4227000 A PT 97621 A,B US 5753233 A	14-11-1991 30-06-1994 14-11-1991 11-11-1991 17-08-1992 31-03-1992 19-05-1998
WO 9626277	A	29-08-1996	AU 4727296 A CA 2211995 A EP 0812358 A JP 11501804 T	11-09-1996 29-08-1996 17-12-1997 16-02-1999
WO 9205248	A	02-04-1992	AU 8762991 A CN 1067382 A	15-04-1992 30-12-1992
DE 4441197	C	28-03-1996	WO 9616181 A EP 0792368 A JP 10508754 T	30-05-1996 03-09-1997 02-09-1998
WO 9322338	A	11-11-1993	AU 675794 B AU 4358693 A AU 7197096 A CA 2112798 A EP 0593754 A JP 7503975 T NZ 253330 A ZA 9303135 A	20-02-1997 29-11-1993 06-02-1997 11-11-1993 27-04-1994 27-04-1995 25-06-1996 02-02-1994
FR 2586428	A	27-02-1987	AT 70280 T CA 1279276 A DE 3682893 A DK 208987 A EP 0235187 A WO 8701375 A GR 862201 A JP 2818745 B JP 8308597 A JP 11023577 A JP 10114677 A JP 2755574 B JP 63500662 T PT 83255 B	15-12-1991 22-01-1991 23-01-1992 26-06-1987 09-09-1987 12-03-1987 23-12-1986 30-10-1998 26-11-1996 29-01-1999 06-05-1998 20-05-1998 10-03-1988 31-07-1989
EP 0386734	A	12-09-1990	DE 3907721 A AT 128144 T AU 624485 B AU 5110490 A CA 2011878 A DE 59009669 D DK 386734 T ES 2078255 T IE 67798 B JP 2289600 A PT 93393 A,B US 5547846 A	20-09-1990 15-10-1995 11-06-1992 13-09-1990 10-09-1990 26-10-1995 05-02-1996 16-12-1995 01-05-1996 29-11-1990 07-11-1990 20-08-1996
WO 9636702	A	21-11-1996	US 5843752 A	01-12-1998

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 98/05285

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9636702 A		AU 5729196 A	29-11-1996
		CA 2220575 A	21-11-1996
		EP 0826038 A	04-03-1998
		JP 10507933 T	04-08-1998
